Eye disorder
MONDO:0005328A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.
Also known as: disease of eye, disease of eyeball of camera-type eye, disease or disorder of eyeball of camera-type eye, disorder of eye, disorder of eyeball of camera-type eye, eye disease, eye disorder, eyeball of camera-type eye disease
2608 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 492 trials in this tab.
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control TerminatedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New eye injection aims to slow vision loss from Age-Related macular degeneration
Disease control OngoingThis study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…
Phase: PHASE4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Contact lenses that could slow nearsightedness in kids
Disease control OngoingThis study tests whether MiSight 1 Day contact lenses can slow the progression of myopia (nearsightedness) in children aged 8 to 12. Participants wear either MiSight 1 Day or standard Proclear 1 day lenses for three years, then all switch to Proclear for one year to see if the ef…
Phase: NA • Sponsor: CooperVision, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could special glasses stop nearsightedness from getting worse?
Disease control ENROLLING_BY_INVITATIONThis study tests whether special spectacle lenses called DIMS (defocus incorporated multiple segment) can slow the progression of nearsightedness (myopia) in university students aged 18 to 23. Participants wear either the DIMS lenses or standard single-vision glasses for comparis…
Phase: NA • Sponsor: University of Bradford • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a blood extract save sight? early trial tests PRP for rare eye diseases
Disease control OngoingThis pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers …
Phase: PHASE1, PHASE2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New eye surgery device put to the test in 205 patients
Disease control OngoingThis study is testing a new device called Virtuoso for eye surgeries like cataract removal and vitrectomy. The goal is to make sure it is safe and works well. About 205 adults who need these surgeries will take part. The study will compare how often problems happen during surgery…
Sponsor: Beaver-Visitec International, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can your own blood help regrow thinning eyebrows?
Disease control OngoingThis study investigates whether injecting platelet-rich plasma (PRP) from a person's own blood can improve mild to moderate eyebrow thinning. Participants receive either PRP or saline injections into the eyebrows, and changes are tracked through photographs over nine months. The …
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental gene therapy aims to halt devastating brain disease in infants
Disease control TerminatedThis study tests a gene therapy called PBKR03 for babies with early infantile Krabbe disease, a severe genetic disorder that damages the brain and nerves. The treatment delivers a working copy of the GALC gene to the brain and body. Researchers will check safety and find the best…
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
One-Time gene therapy aims to halt rare, fatal brain disease in children
Disease control OngoingThis study tests a single dose of PBGM01, a gene therapy delivered directly into the fluid around the brain and spinal cord, in children with GM1 gangliosidosis. The therapy uses a harmless virus to carry a working copy of the GLB1 gene, which is missing or faulty in these patien…
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kidney transplant patients: extended drug trial targets rejection
Disease control ENROLLING_BY_INVITATIONThis study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for brain lining cancer: immunotherapy injected directly into spinal fluid
Disease control OngoingThis early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases
Disease control OngoingThis pilot study tests whether adalimumab, an anti-inflammatory drug, can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants will receive three injections into the eye over four months. The main goal is to see if the t…
Phase: PHASE1, PHASE2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New eye injection aims to halt diabetic vision loss
Disease control OngoingThis study tests an experimental drug called BI 764524, given as an eye injection, in 190 adults with moderate to severe diabetic retinopathy. Participants receive different numbers of injections over a year, and doctors compare eye damage improvements against a sham procedure or…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could donated tissue help heal stubborn wounds? new study investigates
Disease control OngoingThis early-stage study is testing whether a specially prepared membrane made from donated human tissue can help heal chronic wounds, like diabetic foot ulcers and eye surface injuries. The membrane is sterilized with different doses of radiation to find the best balance between s…
Phase: PHASE1 • Sponsor: Libyan Center for Biotechnology Research • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Eye-Directed chemotherapy aims to save sight in children with retinoblastoma
Disease control OngoingThis phase 2 trial tests whether giving chemotherapy directly into the eye (subconjunctival carboplatin) along with systemic topotecan can shrink advanced retinoblastoma tumors in children with disease in both eyes. The goal is to preserve the eye and vision, avoiding removal. Pa…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control TerminatedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a common diabetes drug protect eyesight in stargardt disease?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, can safely slow vision loss in people with ABCA4 retinopathy (Stargardt disease). Fifty-five participants aged 12 and older will take metformin by mouth for 24 months, with regular eye exams to track changes. The go…
Phase: PHASE1, PHASE2 • Sponsor: National Eye Institute (NEI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 people with wet AMD will receive either EYP-1901 or standard aflibercept injections over 2 years. The main goal is to see …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 984 participants will receive injections into the eye every 4 weeks for a yea…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or the standard drug aflibercept. The goal is to see if EYP-1901 can maintain or…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a common cause of vision loss in diabetes. About 1,054 participants receive injections into the eye every 4 weeks for a year, then l…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could special contact lenses slow worsening eyesight in young adults?
Disease control ENROLLING_BY_INVITATIONThis study tests whether dual focus contact lenses (MiSight) can slow the progression of nearsightedness (myopia) in university students aged 18 to 21. Participants wear either the test lenses or standard single vision lenses for at least 10 hours a day. Researchers measure chang…
Phase: NA • Sponsor: University of Bradford • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Laser eye surgery showdown: which fix for nearsightedness is better?
Disease control OngoingThis study compares two common laser eye surgeries—KLEx and FS-LASIK—for treating nearsightedness and astigmatism. Researchers will follow 80 adults aged 21 and older to see which procedure provides better vision without glasses and has fewer side effects. Both surgeries reshape …
Phase: NA • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy shot into both eyes aims to save sight in rare blindness
Disease control OngoingThis study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) in 10 males aged 12-50 with X-linked retinitis pigmentosa, a genetic condition that leads to vision loss. The therapy is injected into both eyes to deliver a working copy of the RPGR gene. The main goal…
Phase: PHASE2 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug hopes to stop relapses in kids with rare nerve disease
Disease control OngoingThis study tests ravulizumab, a drug that calms a part of the immune system, in 12 children with NMOSD – a rare disease where the immune system attacks the nerves in the eyes and spine. The goal is to see if the drug can reduce the number of relapses and prevent disability over a…
Phase: PHASE2, PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy targets autoimmune diseases, but trial never started
Disease control TerminatedThis study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can special lenses slow nearsightedness in kids?
Disease control OngoingThis study tests two types of eyeglass lenses designed to slow the progression of nearsightedness (myopia) in children aged 6 to 13. Over 6 months, researchers will measure changes in eye length and thickness to see how the lenses affect eye growth. The goal is to find a better w…
Phase: NA • Sponsor: Essilor International • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail targets rare eye cancer
Disease control OngoingThis phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
One-Time gene injection aims to halt rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e, a gene therapy that delivers a working copy of the CYP4V2 gene directly into the retina. It is for adults with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The trial will check wh…
Phase: PHASE1, PHASE2 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either tram…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingThis phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple eye treatment stop the need for a corneal transplant?
Disease control OngoingThis registry collects long-term data from hundreds of people in Germany who have undergone corneal cross linking for keratoconus, a condition where the cornea thins and bulges, causing vision loss. The procedure uses riboflavin (vitamin B2) eye drops and UV light to stiffen the …
Sponsor: Suphi Taneri • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New contact lenses aim to slow nearsightedness in kids
Disease control OngoingThis study compares two types of contact lenses for slowing myopia (nearsightedness) in children aged 8 to 14. Over three years, researchers will measure changes in eye length and vision to see if the new lens works as well as the existing one. The goal is to help kids maintain b…
Phase: NA • Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New glasses film may help Kids' eyesight stop getting worse
Disease control OngoingThis study tests special spectacle films designed to slow down myopia (nearsightedness) in children. About 210 kids aged 6 to 14 are taking part. The films use a new technology called S.T.O.P.® that creates changing visual cues, which may help control how fast the eye grows and p…
Phase: NA • Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to restore sight in rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e gene therapy for people with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The therapy delivers a working copy of the CYP4V2 gene directly to the retina. Researchers will measure wh…
Phase: PHASE3 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental gene therapy offers hope for rare blindness condition
Disease control ENROLLING_BY_INVITATIONThis study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The mai…
Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Antioxidant pill shows promise in slowing blindness
Disease control OngoingThis phase 3 trial tests whether an oral antioxidant called N-acetylcysteine (NAC) can slow the loss of vision in people with retinitis pigmentosa, an inherited eye disease that causes gradual blindness. About 485 adults aged 18 to 65 are taking NAC or a placebo for several years…
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Glaucoma implant MINIject put to the test in everyday eye clinics
Disease control OngoingThis registry tracks 320 adults with open-angle glaucoma who receive the MINIject implant, a tiny device placed in the eye to help drain fluid and lower pressure. Researchers collect information on any unexpected complications and how surgeons rate the device's ease of use over t…
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could these eye drops replace cataract surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests an experimental eye drop called ZOC2017217 in 40 people with age-related cataracts. Participants will use the drops twice a day for 24 weeks to see if it improves vision and lens clarity compared to a placebo. The goal is to find a non-surgical option for catarac…
Phase: PHASE2 • Sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a pill replace infusions for gaucher brain symptoms?
Disease control OngoingThis phase 2 trial tests an oral drug called venglustat, given alongside the standard enzyme therapy Cerezyme, in adults with Gaucher disease type 3 (a rare genetic disorder affecting the body and brain). The study has four parts: first, it checks spinal fluid biomarkers to disti…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Glaucoma implant under the microscope: 5-Year safety watch begins
Disease control OngoingThis study follows 116 people with open-angle glaucoma who already have a MINIject implant in their eye. Researchers will track them for up to 5 years to see if any serious device-related problems occur. No new treatment is given—this is a safety check to see how well the implant…
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a new eye drop boost laser results for glaucoma patients?
Disease control OngoingThis study tests whether Rhopressa eye drops can further lower eye pressure in people with glaucoma or high eye pressure who recently had laser surgery (SLT) in both eyes. About 70 adults will receive either Rhopressa or placebo drops daily for several weeks. The goal is to see i…
Phase: PHASE4 • Sponsor: East Coast Institute for Research • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
MS drug may shield eyes from damage, new study hopes to prove
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New study monitors eylea in premature Babies' eye disease
Disease control OngoingThis study follows 75 Japanese babies with retinopathy of prematurity (ROP) who are being treated with Eylea, a drug injected into the eye. ROP causes abnormal blood vessel growth in the retina and can lead to blindness. The study collects real-world data on side effects and how …
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Gene therapy shows promise for rare blindness disease
Disease control OngoingThis study is a follow-up to a Phase 3 trial testing a gene therapy called AAV5-hRKp.RPGR for people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to slow or stop vision decline by delivering a working copy of the RPGR gene …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Engineered immune cells aim to tame autoimmune attacks
Disease control TerminatedThis early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can ear acupressure plus eye drops curb Kids' myopia?
Disease control ENROLLING_BY_INVITATIONThis pilot study tests whether combining low-dose atropine eye drops (0.01% or 0.025%) with ear acupressure can safely slow myopia progression in 420 children aged 6-12. Participants are randomly assigned to one of six groups, including placebo, and are followed for 12 weeks. The…
Phase: NA • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug nipocalimab tested in 655 Sjogren's patients in major trial
Disease control OngoingThis phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Eye implant could replace monthly shots for diabetes-related vision loss
Disease control OngoingThis study tests a small, refillable implant placed in the eye that delivers medication every 24 weeks, compared to standard monthly eye injections. It includes about 634 adults with diabetic macular edema, a condition that causes vision loss. The goal is to see if the implant wo…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Gene therapy targets second eye in rare blindness disorder
Disease control OngoingThis study tests a gene therapy called botaretigene sparoparvovec in the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The 24 participants previously received the therapy in one eye and are now being followed for safety and …
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New eye drug shows promise for Diabetes-Related vision loss
Disease control OngoingThis early-stage study tests a new drug, RO7497372, given as an eye injection for people with diabetic macular edema (DME), a condition that causes vision loss. The trial involves 151 participants and aims to check the drug's safety, how long it stays in the eye and blood, and it…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Fewer needle sticks? study tests larger injector for autoimmune drug
Disease control OngoingThis study tests if a new 2mL auto-injector or pre-filled syringe delivers the same amount of the drug ianalumab into the body as the current 1mL syringe. About 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus will receive the drug both ways to compare how much g…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental gene therapy aims to halt vision loss in rare eye disease
Disease control OngoingThis Phase 3 study tests a gene therapy called AAV5-hRKp.RPGR in 4 Japanese people with X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. The therapy is injected into the eye to deliver a working copy of the RPGR gene. The main goal is to che…
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Bionic eye implant aims to bring back sight in advanced macular degeneration
Disease control OngoingThis study tests a device called the PRIMA System, which includes an implant placed under the retina and a special visual processor worn by the patient. The goal is to help people with advanced dry age-related macular degeneration (geographic atrophy) regain some central vision. …
Phase: NA • Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy after stem cell transplant shows promise for rare brain disease
Disease control OngoingThis study tests a one-time gene therapy infusion (FBX-101) given after a standard stem cell transplant in 6 children with infantile Krabbe disease, a severe genetic disorder affecting the nervous system. The therapy uses a harmless virus to deliver a working copy of the GALC gen…
Phase: PHASE1, PHASE2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
One shot to save sight? gene therapy aims to cut eye injections for wet AMD
Disease control OngoingThis phase 3 trial tests a single injection of 4D-150 gene therapy in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can control the disease as well as or better than standard aflibercept injections given every few weeks. Participa…
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New glasses lens may slow kids' worsening eyesight
Disease control OngoingThis study tests a new type of eyeglass lens designed to slow down nearsightedness (myopia) in children. Fifty kids aged 6 to 15 will wear the special lenses for six months. Researchers will measure changes in the eye's thickness and length to see if the lens works and is safe.
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy shows promise against rare eye cancer
Disease control OngoingThis phase 2 trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink tumors in people with metastatic uveal melanoma, a rare and aggressive eye cancer. Participants receive chemotherapy to prepare their immune system, then an infu…
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingThis study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specif…
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New eye implant aims to lower glaucoma pressure
Disease control ENROLLING_BY_INVITATIONThis study is testing a device called XEN63, a small implant placed in the eye to help drain fluid and lower pressure in people with glaucoma. Researchers will follow 96 patients for 24 months to see if the implant safely reduces eye pressure and the need for daily eye drops. The…
Sponsor: Mario Stirpe • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Syfovre safety check: Real-World study tracks eye drug in 300 patients
Disease control OngoingThis study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug could cut repeat eye surgeries in diabetics
Disease control ENROLLING_BY_INVITATIONThis study tests whether the drug farcimab (Vabysmo), given as an injection before and after eye surgery, can reduce bleeding complications in people with diabetes who have bleeding inside the eye. About 100 adults will receive either farcimab or a sham injection. The goal is to …
Phase: PHASE4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental eye drug shows promise for rare Blindness-Causing disease
Disease control OngoingThis study tests an experimental drug called VP-001 for people with a rare genetic eye disease that causes vision loss. The drug is injected into the eye and aims to slow or stop further damage. Researchers will check safety and measure any changes in eyesight over about two year…
Phase: PHASE1, PHASE2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
CAR-T therapy for autoimmune diseases: study withdrawn before starting
Disease control TerminatedThis study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New eye injection shows promise for blinding swelling
Disease control OngoingThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…
Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug pegtibatinase tested for rare metabolic disorder over two years
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of pegtibatinase in people with classical homocystinuria (HCU), a rare genetic disorder that prevents the body from breaking down certain amino acids. About 100 participants who completed earlier studies will receive the dru…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New lens implant aims to sharpen vision for cataract patients
Disease control OngoingThis study tests a special lens implant that corrects cataracts, presbyopia (need for reading glasses), and astigmatism (blurry vision from an irregularly shaped cornea). The goal is to see if this lens stays stable in the eye and provides good vision at all distances. About 100 …
Phase: NA • Sponsor: Beaver-Visitec International, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eye drops may halt worsening nearsightedness in adults
Disease control OngoingThis study tests whether eye pressure-lowering medication can slow the progression of severe nearsightedness (high myopia) in adults. Researchers will measure changes in eye length and vision over time. The trial includes 152 participants aged 18 to 65 with worsening high myopia …
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New eye drug trial focuses on black, hispanic, and native american patients
Disease control OngoingThis study tests a drug called faricimab (VABYSMO) in 218 people with diabetic macular edema who have not been treated before. The participants are Black/African American, Hispanic/Latino American, Native American/Alaska Native/Native Hawaiian/Pacific Islander, or Asian Indian. T…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a tiny implant replace monthly eye shots for wet AMD?
Disease control OngoingThis study tests an experimental implant (AR-14034) that slowly releases medication inside the eye to treat wet age-related macular degeneration (AMD). The goal is to see if it is safe and can work as well as or better than standard anti-VEGF injections, which require frequent do…
Phase: PHASE1, PHASE2 • Sponsor: Alcon Research • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New eye injection shows promise for Diabetes-Related vision loss
Disease control OngoingThis study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active c…
Phase: PHASE2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 311 people with wet age-related macular degeneration (AMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up treatments. Participants…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New eye surgery could help glaucoma patients ditch drops
Disease control ENROLLING_BY_INVITATIONThis study is watching 300 people with open-angle glaucoma who get a new type of eye surgery called bio-reinforced canaloplasty. The surgery aims to improve fluid drainage inside the eye to lower pressure. Participants will have regular eye check-ups for two years to see how well…
Sponsor: Iantrek, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could an implant replace daily eye drops for glaucoma?
Disease control OngoingThis study tests an implant called AGN-193408 SR that is placed inside the eye to lower pressure in people with open-angle glaucoma or ocular hypertension. About 100 participants will receive the implant, and some will also get standard eye drops for comparison. The goal is to se…
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New laser could ease glaucoma without drops
Disease control OngoingThis study tests a new laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) in 40 ethnic Chinese patients with glaucoma or high eye pressure. The laser aims to improve fluid drainage in the eye and reduce pressure. Researchers will check if the treatment is safe a…
Phase: NA • Sponsor: BelkinVision • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill could slow blindness in inherited eye disease
Disease control OngoingThis early-stage trial tests a new oral drug called OCT-980 for people with a specific inherited eye disease (autosomal dominant retinitis pigmentosa) that causes gradual vision loss and blindness. The study first gives a single dose to healthy volunteers to check safety, then mu…
Phase: PHASE1, PHASE2 • Sponsor: Octant, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
One-Patient trial hopes to slow rare eye and nerve disease
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests an experimental drug called nL-FLVC-001 in a single person with posterior column ataxia with retinitis pigmentosa (PCARP), a rare genetic condition that causes vision loss and coordination problems. The drug is an antisense oligonucleotide injected in…
Phase: EARLY_PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a daily injection save your sight? new trial for dry AMD
Disease control OngoingThis phase 3 trial tests whether a daily injection of elamipretide can slow vision loss in people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early dry AMD will receive either the drug or a placebo for 96 weeks. The main goal is to see…
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New glasses film aims to stop kids' eyesight from getting worse
Disease control OngoingThis study tests whether a special film applied to glasses can slow the progression of nearsightedness (myopia) in children aged 6 to 14. The film uses A.R.R.E.S.T.® technology, which is designed to send specific light signals to the eye to control its growth. Over two years, res…
Phase: NA • Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New eye drop targets Mite-Related eyelid inflammation in phase 2 trial
Disease control OngoingThis study tests a new eye drop (APT-001, containing spinosad 1.8%) for blepharitis, a condition causing red, irritated eyelids often linked to tiny mites. About 100 people with symptoms will receive either the active drop or a placebo. The goal is to see if the treatment clears …
Phase: PHASE2 • Sponsor: Aperta Biosciences, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New glasses could slow kids' worsening eyesight
Disease control OngoingThis study tests whether special glasses with P.A.U.S.E. technology can slow the progression of nearsightedness (myopia) in children. About 205 Vietnamese children aged 6-14 will wear either the special lenses or regular glasses for one year, then all will wear the special lenses…
Phase: NA • Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Telescope eye implant study for AMD withdrawn before it began
Disease control TerminatedThis study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug shows promise in Late-Stage Sjogren's trial
Disease control OngoingThis phase 3 study tests whether the drug ianalumab can reduce disease activity in people with active Sjogren's syndrome. About 275 adults with the condition will receive either ianalumab or a placebo shot under the skin. The main goal is to see if the drug improves symptoms and …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Eye-Opening study: amino acids may slow nearsightedness in young adults
Disease control OngoingThis study tests whether taking branched-chain amino acid (BCAA) supplements for six months can slow the progression of myopia (nearsightedness) in young adults aged 18 to 25. Participants either receive BCAA supplements plus standard glasses or a placebo plus glasses. The goal i…
Phase: NA • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
One-Time eye injection could slow blindness in retinitis pigmentosa
Disease control OngoingThis study tests a gene therapy called SPVN06 for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment is given as a single injection under the retina. The trial includes 33 adults with advanced disease and will check safety and whether it…
Phase: PHASE1, PHASE2 • Sponsor: SparingVision • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye drug takes on leading cause of blindness in the elderly
Disease control OngoingThis study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye drop shows promise for glaucoma control in chinese patients
Disease control OngoingThis study tests a new eye drop called DE-117B in 345 Chinese adults with open-angle glaucoma or high eye pressure. The goal is to see if it safely lowers eye pressure better than an existing drug. Participants use the drops once daily for at least 4 weeks, with long-term follow-…
Phase: PHASE3 • Sponsor: Santen Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Eye-Strengthening light therapy tested to halt blinding cornea disease
Disease control OngoingThis phase 3 trial tests a procedure called corneal collagen crosslinking for people with progressive keratoconus, a condition where the cornea thins and bulges, blurring vision. The treatment uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea. The study aims t…
Phase: PHASE3 • Sponsor: Sahlgrenska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye drop aims to lower glaucoma pressure
Disease control OngoingThis Phase 2 trial tests an experimental eye drop called BL1107 against a standard treatment (timolol) in 252 adults with glaucoma or high eye pressure. Participants use the drops twice daily for 28 days. The study measures changes in vision and eye pressure to see if BL1107 is s…
Phase: PHASE2 • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Laser combo may cut eye injection burden for vein blockage patients
Disease control OngoingThis study looks at whether adding targeted laser treatment to the standard ranibizumab injections can help people with macular edema (swelling) from a central retinal vein occlusion need fewer injections over time. About 88 adults with this condition will receive either injectio…
Phase: PHASE3 • Sponsor: University of Giessen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New eye injection targets Blindness-Causing lesions
Disease control OngoingThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Eye transplant showdown: which surgery saves sight best?
Disease control OngoingThis study compares two types of corneal transplant surgery (UT-DSAEK and DMEK) in 160 people with Fuchs dystrophy, a condition that clouds the cornea. It also tests whether a drug called rho-kinase inhibitor can reduce loss of important eye cells after surgery. The goal is to fi…
Phase: PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New eye implant could cut treatment visits to twice a year for wet AMD
Disease control OngoingThis phase 3 trial tests whether a refillable eye implant delivering ranibizumab can be safely used every 36 weeks instead of every 24 weeks for people with wet age-related macular degeneration. About 451 participants who have already responded to standard injections will receive…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New lens aims to match top cataract implant in vision quality
Disease control OngoingThis study compares a new domestic trifocal lens (D615L) to the Zeiss AT LISA tri 839MP for people having cataract surgery. 90 adults with age-related cataracts will receive one of the two lenses and be followed for 6 months to measure vision at different distances. The goal is t…
Sponsor: Shanghai 10th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThis study tests whether monthly eye injections of ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection. The main goa…
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New glasses could slow Kids' nearsightedness over 3 years
Disease control OngoingThis study tests special glasses with Diffusion Optics Technology to see if they can slow the progression of nearsightedness (myopia) in children. About 200 kids who completed a previous study will wear these glasses for up to 3 years. Researchers will measure changes in eye leng…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye drug implant could reduce injections for wet AMD
Disease control OngoingThis study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant placed in the eye that releases the drug over time. The trial involv…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New glasses aim to stop kids' eyesight from getting worse
Disease control OngoingThis 3-year study tests whether a new type of spectacle lens can slow the progression of nearsightedness (myopia) in children aged 6 to 10. A total of 266 kids will wear either the novel lenses or standard lenses, and researchers will measure changes in eye length and prescriptio…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New glasses could help Kids' eyesight stop getting worse
Disease control OngoingThis trial tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can slow the progression of nearsightedness (myopia) in Chinese children aged 6 to 13. Over 12 months, 195 children will wear either the DOT lenses or standard single-vision lenses. …
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Liver-Directed chemo shows promise for eye cancer metastases
Disease control OngoingThis phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye drug trial aims for safer wet AMD treatment
Disease control OngoingThis early-stage trial tests an experimental drug called OCU-10-C-110, given as an eye injection, in 24 people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability at different doses. Researchers will monitor for side effects over ti…
Phase: PHASE1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Lab-Grown eye cells injected to reverse corneal blindness
Disease control OngoingThis early-stage trial tests whether injecting cultured corneal endothelial cells into the eye can repair damaged corneas and improve vision. Twelve adults with corneal swelling and poor eyesight received a single injection of donor cells grown in a lab. The goal is to see if the…
Phase: PHASE1 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a diabetes drug protect your eyes? 5-Year trial seeks answers
Disease control OngoingThis study looks at whether semaglutide, a medicine for type 2 diabetes, can slow or prevent diabetic eye disease over 5 years. About 1500 adults with type 2 diabetes will receive either semaglutide or a placebo injection once a week, in addition to their usual diabetes medicatio…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:27 UTC
-
New eye drug could cut wet AMD shots to just twice a year
Disease control OngoingThis study tests whether faricimab, an already-approved eye injection, can be given every 24 weeks (about twice a year) to people newly diagnosed with wet age-related macular degeneration (AMD). The trial involves 274 participants and will measure how well vision is maintained ov…
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Gene therapy watch: RGX-111 safety tracked in MPS i patients
Disease control ENROLLING_BY_INVITATIONThis study checks the long-term safety of RGX-111, a gene therapy for people with MPS I (a rare genetic disorder). It follows 21 participants who already received the therapy in an earlier trial. Researchers will monitor side effects and measure changes in thinking and behavior o…
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Stem cells injected into eye aim to halt blindness
Disease control OngoingThis study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damag…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Tiny eye implant aims to lower glaucoma pressure
Disease control OngoingThis study tests a small device called XEN45 that is implanted in the eye to help drain fluid and lower pressure in people with open-angle glaucoma. About 120 adults in China will receive either the XEN45 implant or standard glaucoma surgery. Researchers will track eye pressure a…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New eye drop combo aims to soothe dry eyes fast
Disease control ENROLLING_BY_INVITATIONThis study tests whether using two eye drops together—Vevye (cyclosporine) and Flarex (a steroid)—can safely improve symptoms in adults with moderate to severe dry eye disease. Sixty participants will use Vevye twice daily and Flarex four times daily for one month. The goal is to…
Phase: PHASE4 • Sponsor: Canyon City Eyecare • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Sjögren's drug ianalumab tested for Long-Term safety in 600-Patient trial
Disease control OngoingThis phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for wet AMD: two novel drugs enter final testing phase
Disease control OngoingThis Phase 3 study tests two new drugs, tarcocimab tedromer and tabirafusp tedromer, against the standard treatment aflibercept for wet age-related macular degeneration (AMD). The trial involves 675 participants who have not been treated before. The goal is to see if the new drug…
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a tiny eye implant replace daily drops for glaucoma?
Disease control OngoingThis early-stage trial is testing a single biodegradable implant placed in the eye to lower pressure in people with open-angle glaucoma or ocular hypertension. The implant slowly releases medication over time and then dissolves. The study includes 12 adults and focuses on safety,…
Phase: PHASE1 • Sponsor: PolyActiva Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New lenses aim to slow Kids' nearsightedness
Disease control OngoingThis study tests whether special new spectacle lenses can slow the worsening of nearsightedness (myopia) in children. About 342 kids aged 7 to 13 will wear either the new lenses or standard single-vision glasses for one year, then all switch to the new lenses for another year. Th…
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with eye inflammation: baricitinib trial shows promise
Disease control OngoingThis study tests whether baricitinib, an oral drug, is safe and effective for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. Participants had not responded well to standard treatments. The main goal is to reduce e…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can special lenses plus eye drops stop Kids' myopia from getting worse?
Disease control OngoingThis study tests whether combining special glasses (that create optical defocus) with low-dose atropine eye drops can better control myopia (nearsightedness) in children aged 7 to 12. Over 18 months, researchers will measure changes in eye prescription and eye length. The goal is…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eye implant aims to ease glaucoma pressure
Disease control OngoingThis study tests a small implant placed inside the eye to help drain fluid and lower pressure in people with open-angle or narrow-angle glaucoma. It is for adults whose eye pressure is not well controlled with eye drops. The main goal is to see if the implant safely reduces press…
Phase: NA • Sponsor: Ciliatech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a zapping headband save your sight?
Disease control OngoingThis study tests whether long-term, mild electrical stimulation using a home device can safely slow vision loss in people with open-angle glaucoma. About 45 adults with moderate vision damage will use the device regularly. The goal is to see if this approach can protect the optic…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Special lenses could slow worsening eyesight in kids
Disease control OngoingThis study tests a new type of spectacle lens (DG2) designed to slow down nearsightedness (myopia) in children whose vision is getting worse quickly. 118 children aged 4–13 will wear these lenses for 4 years. Researchers will measure changes in their eye prescription and eye leng…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThis study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Phase: PHASE2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Special lenses aim to halt rapid vision decline in kids
Disease control OngoingThis study tests two types of special glasses (DIMS and D2 lenses) to see if they can slow down worsening nearsightedness in children whose vision is getting worse quickly. About 59 children will wear these glasses for 4 years, and researchers will measure changes in their eyesig…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental antibody takes aim at eye inflammation
Disease control OngoingThis study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New nomogram may sharpen vision in keratoconus patients
Disease control OngoingThis study tests whether a new surgical guide (the Alfonso nomogram) helps doctors place corneal ring implants more effectively in people with moderate keratoconus. Twenty-five adults aged 18–35 with progressive disease received the implant. Researchers will measure changes in vi…
Phase: NA • Sponsor: Assiut University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can fewer eye injections work just as well? new trial tests flexible dosing for diabetic macular edema
Disease control OngoingThis study compares two ways of giving faricimab, a drug injected into the eye, to treat diabetic macular edema (DME). One group gets injections on a fixed monthly schedule, while the other uses a 'treat and extend' approach where the time between injections is gradually lengthen…
Phase: PHASE4 • Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New lens implants promise clear vision at all distances after cataract surgery
Disease control OngoingThis study tests two types of advanced lens implants (IOLs) for people having cataract surgery in both eyes. The lenses are designed to help see clearly at far, arm's length, and near distances. Researchers will check safety and how well the lenses work in 110 participants over t…
Phase: NA • Sponsor: Alcon Research • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot could tame Sjögren's symptoms in major trial
Disease control OngoingThis phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Last-Chance access: experimental eye treatment opens for 75 RP patients
Disease control NO_LONGER_AVAILABLEThis program offers an experimental treatment called OCU400 to up to 75 adults with retinitis pigmentosa (RP) who cannot join the main Phase 3 study. Participants must be 18 or older, have a confirmed genetic diagnosis of RP (except a specific mutation), and have remaining light-…
Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for rare eye cancer: drug targets spreading tumors
Disease control OngoingThis study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New UV laser could make LASIK safer and more precise
Disease control OngoingThis study tests a new ultraviolet femtosecond laser for creating corneal flaps during LASIK surgery to correct refractive errors. About 128 participants in Australia will receive LASIK using either the new UV laser or an existing infrared laser. The main goal is to check how saf…
Phase: NA • Sponsor: Alcon Research • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Eye implant may delay cataracts after vitrectomy
Disease control OngoingThis study tests a special implant placed in the eye during vitrectomy surgery to see if it can safely slow down cataract formation. About 30 adults who need vitrectomy and already have some cataract will receive the implant. The goal is to delay cataract progression, possibly re…
Phase: PHASE1, PHASE2 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy for wet AMD: 4-Year safety check begins
Disease control OngoingThis study checks the long-term safety of a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (AMD), a condition that can cause severe vision loss. Participants already received the gene therapy in an earlier study and will be monitored for up …
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Gene therapy offers hope for rare Blindness-Causing eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive one of two doses of the therapy or no treatment, and researchers measure changes in vision under low ligh…
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo shows promise against rare eye cancer
Disease control OngoingThis study tests whether combining two drugs, binimetinib and belinostat, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 7 adults with this condition are taking part. The main goal is to see how many patients respond to the tr…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New lens design aims to halt worsening eyesight in children
Disease control ENROLLING_BY_INVITATIONThis study tests whether specially designed eyeglass lenses can slow the progression of myopia (nearsightedness) in children aged 6 to 14. Researchers will measure changes in eye length and prescription over time, while also checking for safety and comfort. The goal is to find a …
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingThis study tests a new gene therapy called OCU410ST for people with Stargardt disease, an inherited eye condition that causes vision loss. Early results show the treatment slowed damage to the retina by nearly half and improved or stabilized eyesight in all treated patients. The …
Phase: PHASE2, PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a Parkinson's drug protect eyes in diabetes?
Disease control ENROLLING_BY_INVITATIONThis study tests whether levodopa, a drug used for Parkinson's, can slow blood vessel changes in the eyes of people with diabetes. Researchers will give the drug or a placebo to 244 patients with early diabetic retinopathy and measure retinal electrical activity and imaging over …
Phase: EARLY_PHASE1 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Radioactive drug trial aims at rare eye cancer
Disease control OngoingThis early-phase trial tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the highest safe dose and understand side effects. Participants receive a singl…
Phase: PHASE1 • Sponsor: Modulation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Bionic eye implant aims to restore sight in dry AMD patients
Disease control OngoingThis early feasibility trial tests a new retinal implant called PRIMA in 5 people with advanced dry age-related macular degeneration who have lost central vision. The device is surgically placed in the eye to stimulate remaining retinal cells. Researchers are checking if it is sa…
Phase: NA • Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could vitamin B3 save sight in rare optic nerve disease?
Disease control OngoingThis study tests whether high-dose nicotinamide (vitamin B3) is safe and can help people with dominant optic atrophy, a rare genetic disease that slowly damages the optic nerve and causes vision loss. Researchers will give 25 adults 3 grams of nicotinamide daily and monitor for s…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill could tame Sjögren's syndrome
Disease control OngoingThis phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug aims to boost immune system against advanced cancers
Disease control OngoingThis early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…
Phase: PHASE1 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingThis early-phase trial is testing a single-dose gene therapy called LY3884961 in 7 infants with Type 2 Gaucher disease, a severe and rapidly fatal genetic disorder. The therapy is injected into the fluid around the brain and spinal cord to deliver a working copy of the faulty gen…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New transplant approach aims to cure blood failure without harming lungs or liver
Disease control OngoingThis study tests a bone marrow transplant method that avoids harsh chemotherapy and radiation for people with dyskeratosis congenita, a genetic disorder causing bone marrow failure. The goal is to fix the blood system without worsening lung or liver disease or raising cancer risk…
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New implant could replace eye drops after corneal surgery
Disease control ENROLLING_BY_INVITATIONThis study tests whether a tiny steroid-releasing implant (Dextenza) placed in the tear duct works as well as standard steroid eye drops after corneal crosslinking surgery for keratoconus. About 20 people aged 13 and older with progressive keratoconus will receive either the impl…
Phase: PHASE1, PHASE2 • Sponsor: Maanasa Indaram, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New lens injector aims to sharpen cataract surgery outcomes
Disease control OngoingThis study tests a new preloaded lens delivery system for cataract surgery in 200 adults aged 40 and older. The device is designed to simplify the procedure and reduce handling of the lens. Researchers will measure how well patients see after surgery and how surgeons rate the sys…
Phase: NA • Sponsor: Istanbul University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can special glasses stop Kids' eyesight from getting worse?
Disease control OngoingThis study tests whether new spectacle lenses can safely slow the progression of myopia (nearsightedness) in children. About 249 kids will wear either the novel lenses or standard single vision glasses for 36 months. Researchers will measure changes in eye length and prescription…
Phase: NA • Sponsor: HOYA Lens Thailand LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immune cell therapy shows promise for Hard-to-Treat melanoma
Disease control OngoingThis study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New eye implant aims to lower pressure in glaucoma patients
Disease control OngoingThis early study tests a new drainage device for people with glaucoma, a condition where pressure builds up in the eye. The device is designed to self-adjust to help lower eye pressure. Ten participants will be followed to see if the device is safe and effective at reducing press…
Phase: PHASE1 • Sponsor: Rheon Medical SA • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gas-Free eye surgery could revolutionize macular hole repair
Disease control OngoingThis study tests a new surgical technique to close macular holes in people with high myopia without using a gas bubble. The standard approach requires a gas bubble that blurs vision and forces patients to keep their head down for days. The new method uses a gel-like substance to …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for diabetic eyes: stronger dose may stop vision loss
Disease control OngoingThis study tests a higher dose (8mg) of aflibercept in 40 adults with proliferative diabetic retinopathy (PDR) who do not have swelling in the center of the retina. The goal is to see if this treatment can improve the severity of the disease and maintain vision over 96 weeks. Par…
Phase: PHASE4 • Sponsor: Edward Wood, MD • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can two existing drugs keep eye cancer from spreading?
Disease control OngoingThis phase 2 trial tests whether sunitinib or valproic acid can prevent uveal melanoma, a rare eye cancer, from spreading to other parts of the body in high-risk patients. 210 participants who have already had their primary tumor treated are randomly assigned to receive one of th…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New lotion could ease rare skin disorder
Disease control OngoingThis study tests a lotion called QRX003 in 30 people with Netherton Syndrome, a rare genetic skin condition. The lotion contains a drug that blocks certain enzymes thought to cause skin problems. Researchers are checking if it reduces redness, scaling, and itching compared to a p…
Phase: PHASE2, PHASE3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill could save eyes from melanoma surgery
Disease control OngoingThis phase 2 trial tests darovasertib, a daily pill, in 160 people with uveal melanoma (a rare eye cancer). The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if the pill can shrink tumors enough to avoid eye removal, reduc…
Phase: PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Gene therapy trial for rare childhood disease halted Mid-Study
Disease control TerminatedThis study tests a gene therapy called RGX-111 for people with MPS I, a rare genetic disorder that damages the brain and body. The therapy delivers a working copy of the missing IDUA gene directly into the fluid around the brain. The trial aims to check if the treatment is safe a…
Phase: PHASE1, PHASE2 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New glasses lens could slow Kids' nearsightedness
Disease control OngoingThis study tests whether a special lens called Blue Star MAX-5 can slow the progression of nearsightedness (myopia) in children aged 8 to 11. Two hundred kids will wear either the new lens or standard glasses and be checked every six months for two years. The goal is to see if th…
Phase: NA • Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThis study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…
Phase: PHASE2, PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis study tests a new gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is to chec…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a daily shot help kids with rare bone diseases grow?
Disease control OngoingThis early study tests a daily injection of vosoritide (Voxzogo) in 6 children aged 5 to 10 with MPS IVA or VI, rare conditions that cause growth problems. The main goal is to see if the drug is safe and tolerable over 96 weeks. Researchers will also look at changes in height and…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
One-Time gene injection aims to restore sight in rare eye disease
Disease control OngoingThis phase 3 trial tests a gene therapy called LX101 in 30 people with inherited retinal dystrophy caused by RPE65 mutations. Participants receive a single injection of LX101 into the eye, while a control group gets no treatment. The study measures changes in functional vision an…
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Gene therapy trial aims to restore night vision in rare eye disease
Disease control OngoingThis study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an inherited eye disease that causes vision loss. The treatment is injected under the retina to help light-sensitive cells work better. The trial enrolled 140 people aged 3 and older and measures …
Phase: PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental gene therapy aims to restore sight in rare eye disease
Disease control OngoingThis early study tests a gene therapy called LX101 in 9 people with a rare inherited eye disease caused by RPE65 gene mutations. The therapy delivers a working copy of the gene into the retina via a single injection. The main goals are to check safety and see if it can improve vi…
Phase: PHASE1 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-and-Done gene shot could spare wet AMD patients from monthly eye needles
Disease control OngoingThis phase 2 trial tests a gene therapy called LX102 for wet age-related macular degeneration (nAMD), a leading cause of vision loss. The therapy is injected under the retina and aims to produce a protein that blocks abnormal blood vessel growth, potentially reducing the need for…
Phase: PHASE2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Desperate hope: gene therapy tested in one patient with rare blindness
Disease control NO_LONGER_AVAILABLEThis expanded access program gave a single patient with Leber Hereditary Optic Neuropathy (a genetic cause of vision loss) an experimental gene therapy called GS010. The treatment was injected into both eyes to test safety. Only one person was involved, so the results are very li…
Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
Disease control OngoingThis early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal …
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Rapamycin drug tested for rare castleman disease
Disease control OngoingThis phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph no…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as one or two injections into the eye and aims to produce proteins that block abnormal blood vessel growth, potentially replacing …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New gene therapy aims to fix immune system in rare disease
Disease control ENROLLING_BY_INVITATIONThis study tests a new gene therapy for people with chronic granulomatous disease (CGD), a genetic disorder that weakens the immune system and makes them prone to serious infections. The treatment takes the patient's own blood stem cells, adds a missing gene in the lab, and puts …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Gene therapy injection aims to restore sight in rare eye diseases
Disease control OngoingThis early-phase trial tests a single injection of a gene therapy called RTx-015 in 10 adults with retinitis pigmentosa or choroideremia, two inherited conditions that cause vision loss. The therapy delivers a gene that makes retinal cells produce a light-sensitive protein, poten…
Phase: PHASE1 • Sponsor: Ray Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to slow vision loss in Age-Related blindness
Disease control OngoingThis study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New implant offers hope for glaucoma patients failing drops
Disease control OngoingThis early study tests a new device called the GORE Glaucoma Drainage Implant in 30 adults with primary open-angle glaucoma that eye drops cannot control or who are at high risk of scarring from standard surgery. The goal is to see if the implant safely lowers eye pressure by at …
Phase: NA • Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a stronger eylea dose cut eye injections in half?
Disease control OngoingThis study tests whether switching wet AMD patients who don't respond well to the standard 2mg dose of aflibercept (Eylea) to a higher 8mg dose can extend the time between injections while keeping vision stable. Fifty adults who have already had at least four 2mg injections will …
Sponsor: Vienna Institute for Research in Ocular Surgery • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New glasses aim to halt adult nearsightedness
Disease control OngoingThis study tests whether Essilor Stellest spectacle lenses can slow the progression of nearsightedness (myopia) in adults aged 18 to 40. Each participant wears a Stellest lens in one eye and a standard lens in the other, allowing direct comparison. The trial measures changes in e…
Phase: NA • Sponsor: University of Ulster • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to fight deadly eye cancer
Disease control OngoingThis study tests a combination of two oral drugs, darovasertib and crizotinib, against standard treatments (immunotherapy or chemotherapy) in 420 people with a specific type of advanced eye melanoma that has spread. Participants must have a certain genetic marker (HLA-A2 negative…
Phase: PHASE2, PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New software may sharpen laser eye surgery for blurry vision
Disease control OngoingThis study tests a software program that predicts how much vision improvement a special laser treatment can provide for people with irregularly shaped corneas causing astigmatism. About 45 participants with vision quality issues will have their eyes treated, and the software's pr…
Phase: NA • Sponsor: London Vision Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a lower dose of avastin save sight in preemies?
Disease control OngoingThis study tests whether lower doses of the drug bevacizumab (Avastin) can effectively treat a severe form of retinopathy of prematurity (ROP) in premature infants. The trial includes 77 babies with type 1 ROP in zone I, the most dangerous type. Each infant receives a single inje…
Phase: PHASE2 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Gene therapy aims to restore sight in rare blindness condition
Disease control OngoingThis phase 3 trial tests a gene therapy called NR082 for Leber's hereditary optic neuropathy (LHON), a genetic condition that causes rapid vision loss. About 95 people aged 12 to 75 with a specific ND4 mutation will receive a single injection of the therapy or a sham procedure. T…
Phase: PHASE3 • Sponsor: Wuhan Neurophth Biotechnology Limited Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
One-Shot gene therapy could replace monthly eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for frequent anti-VEGF injections by helping t…
Phase: PHASE1, PHASE2 • Sponsor: Avirmax Biopharma Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New fluid lens could sharpen vision after cataract surgery
Disease control OngoingThis study tests a new type of lens implant for people having cataract surgery. The lens uses fluid to adjust focus, aiming to improve vision compared to a standard fixed-focus lens. About 175 participants will receive either the new lens or a standard one, and their vision and a…
Phase: NA • Sponsor: Alcon Research • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Gene therapy for wet AMD: could this mean fewer eye injections?
Disease control OngoingThis study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the n…
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
First gene therapy trial launches for rare childhood disease MLIV
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a gene therapy called AAV9.hMCOLN1co in one child with Mucolipidosis Type IV (MLIV), a rare genetic disorder. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety, but researchers will also look for any si…
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could Lab-Grown eye cells restore sight? new trial begins
Disease control OngoingThis early-stage study tests whether stem cells grown from a patient's own eye can be safely transplanted to repair the cornea in people with limbal stem cell deficiency, a condition that causes vision loss. Twenty adults with severe vision loss will receive the transplant, and r…
Phase: PHASE1 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control TerminatedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control TerminatedThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New eye drops aim to halt Vision-Threatening keratoconus
Disease control ENROLLING_BY_INVITATIONThis early study tests whether TN-001 eye drops are safe and can stop keratoconus, a disease that thins and bulges the cornea, from getting worse. About 20 adults with progressive keratoconus will use the drops twice daily for 3-6 weeks. Researchers will monitor for side effects …
Phase: PHASE1, PHASE2 • Sponsor: TheiaNova Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Gene therapy shot aims to fix gaucher disease in kids
Disease control OngoingThis early-phase trial tests a single intravenous dose of LY-M001 gene therapy in 9 children (ages 6 to 17) with type 1 Gaucher disease. The goal is to see if it is safe and can improve key symptoms like liver size and blood markers. Researchers will monitor participants for side…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can allergy shots work as well for kids as adults? new study aims to find out.
Disease control OngoingThis 5-year study is looking at how well a year-round allergy treatment (MATA trees or MATA grass) works for children and adults with pollen allergies, including hay fever and mild asthma. Researchers want to see if the treatment is as effective in kids as it is in adults. About …
Sponsor: Allergy Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Eye shape secrets: can drops or contacts slow nearsightedness?
Disease control OngoingThis study tracks 75 nearsighted young adults over 12 months to see how low-dose atropine eye drops or soft multifocal contact lenses affect the shape of the eye. Participants are randomly assigned to one of these treatments or no treatment. Researchers will take eye photos and m…
Phase: PHASE4 • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Custom 3D-Printed jaw implants put to the test against traditional surgery
Disease control OngoingThis study compares two standard ways to fix jaw position after surgery: custom 3D-printed titanium implants (PSIs) versus traditional metal plates that surgeons bend during the operation. Researchers will check how accurately the bones are placed right after surgery and how stab…
Phase: NA • Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Stem cells injected into eyes: a new hope for blindness?
Disease control OngoingThis early-stage trial is testing whether it is safe to inject a person's own bone marrow stem cells into their eye to treat vision loss from conditions like macular degeneration and diabetic retinopathy. Fifteen adults with severe vision loss will receive the injection and be mo…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New eye drops could help kids see clearly longer
Disease control OngoingThis study tests a new eye drop called SHJ002 to see if it can safely slow down worsening nearsightedness (myopia) in children ages 3 to 12. The drop works by targeting a specific molecule in the eye. Researchers will compare it to a standard treatment, atropine, and measure chan…
Phase: PHASE2 • Sponsor: Sunhawk Vision Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New eye injection aims to slow genetic blindness
Disease control OngoingThis study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a common Anti-Inflammatory eye drop slow diabetic vision loss?
Disease control OngoingThis study tests whether ketorolac, an anti-inflammatory eye drop, can reduce inflammation in the eyes of people with diabetic retinopathy and slow the disease. About 164 adults with type 2 diabetes will use either the active drop or a placebo for up to 3 years. Researchers will …
Phase: PHASE1 • Sponsor: Stephen J. Kim, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Gene therapy shot could end frequent eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…
Phase: PHASE1, PHASE2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Common heart drug may shield eyes of type 1 diabetes patients
Disease control OngoingThis study tests whether fenofibrate, a drug typically used to lower blood fats, can slow the worsening of diabetic retinopathy (eye damage) in adults with type 1 diabetes. Over 400 participants take either fenofibrate or a placebo daily for three years. The goal is to see if the…
Phase: PHASE3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Gene therapy for macular degeneration: is it safe years later?
Disease control OngoingThis study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…
Phase: PHASE1 • Sponsor: Oxford BioMedica • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Sjögren's sufferers
Disease control OngoingThis Phase 3 trial tests dazodalibep, a drug given by IV, in 651 people with moderate-to-severe Sjögren's syndrome. The goal is to see if it reduces disease activity and improves symptoms like dryness and fatigue. Participants receive either the drug or a placebo, and researchers…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise in Hard-to-Treat eye cancer
Disease control OngoingThis phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…
Phase: PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Adjustable lens study tracks Long-Term vision results
Disease control ENROLLING_BY_INVITATIONThis study follows about 500 people who already had cataract surgery with a special adjustable lens (RxSight LAL) or a standard lens. Researchers want to see how well the lens works over time, focusing on vision sharpness and correction of astigmatism. Participants just need to c…
Sponsor: RxSight, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill could tame debilitating eye inflammation, major trial underway
Disease control OngoingThis study tests an oral medication called brepocitinib in adults with active uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can prevent the disease from worsening and help maintain vision. About 371 participants will receive either the d…
Phase: PHASE3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Double surgery combo may help glaucoma patients see better outcomes
Disease control ENROLLING_BY_INVITATIONThis study reviews 100 patients with open-angle glaucoma who had two minimally invasive surgeries (Hydrus microstent and iTrack canaloplasty) along with cataract surgery. Researchers want to see if this combination lowers eye pressure and reduces the need for glaucoma medications…
Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
One shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for kids with eye cancer: extra chemo may stop spread
Disease control OngoingThis study looks at whether giving chemotherapy (and sometimes radiation) after removing the eye can prevent retinoblastoma from coming back in children. About 195 children with advanced retinoblastoma in one eye took part. The goal is to see if this extra treatment reduces the c…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New stem cell approach aims to tame rare genetic diseases
Disease control OngoingThis study tests a stem cell transplant method for people with inherited metabolic disorders and severe osteopetrosis. The goal is to get the donor cells to take hold while keeping side effects low. Participants receive chemotherapy drugs before the transplant to prepare their bo…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a single gene shot replace monthly eye injections for wet AMD?
Disease control OngoingThis early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New injection could shrink skin cancer before surgery
Disease control OngoingThis study tests an experimental drug called RP1 that is injected directly into skin cancer tumors. The goal is to see if it can shrink or eliminate the cancer before surgery. Up to 12 adults with a type of skin cancer called cutaneous squamous cell carcinoma will take part. The …
Phase: PHASE1, PHASE2 • Sponsor: Sherrif Ibrahim • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gene therapy injection aims to halt blindness from rare eye disorder
Disease control OngoingThis Phase 3 trial tests a gene therapy called VGR-R01 for Bietti crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The study will enroll 45 adults who receive either the gene therapy injection under the retina or a control treatment. Resear…
Phase: PHASE3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gene therapy trial aims to halt blindness from rare crystal disease
Disease control OngoingThis early-stage trial tests a gene therapy called VGR-R01 for Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to progressive vision loss. The study involves 12 adults who receive the therapy via injection into the eye. The main goal is to check safety and t…
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Gene therapy could replace risky transplants for kids with hurler syndrome
Disease control OngoingThis Phase 3 trial tests a new gene therapy called OTL-203 against the standard stem cell transplant for children with Hurler syndrome, a rare genetic disorder. The therapy uses the child's own blood stem cells, modified to produce the missing enzyme, aiming to improve survival a…
Phase: PHASE3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New glaucoma surgery under the microscope: 300 patients tracked for 2 years
Disease control ENROLLING_BY_INVITATIONThis study follows 300 adults with open-angle glaucoma who had a surgery called CycloPen™ to lower eye pressure. Researchers will check if the surgery safely reduces eye pressure by at least 20% and if patients need fewer eye drops over 24 months. The goal is to see how well this…
Sponsor: Iantrek, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…
Phase: PHASE1, PHASE2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a common arthritis drug tame Sjogren's syndrome?
Disease control OngoingThis early-phase trial is testing the safety of tofacitinib (Xeljanz), a drug already used for rheumatoid arthritis, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants take the drug or a placebo daily for 168 days. The goal is to see if the drug is safe and toler…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktails aim to beat river blindness
Disease control OngoingThis study tests four different drug combinations in 300 adults with onchocerciasis (river blindness), a parasitic disease. Participants first receive ivermectin to clear skin and eye parasites, then get one of the new combos. The goal is to see which combo is safest and most eff…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Light-Activated dye could save sight from severe eye infections
Disease control OngoingThis study tests whether a light-activated dye called rose Bengal, combined with antibiotics and steroids, can improve vision in people with severe bacterial eye infections. About 60 adults with corneal ulcers and vision loss will receive either the dye treatment or a sham proced…
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for rare autoimmune disease: eculizumab trial targets relapses
Disease control OngoingThis study tests a drug called eculizumab in Chinese adults with a rare autoimmune disease called NMOSD, which attacks the nerves in the eyes and spinal cord. The goal is to see if the drug can reduce the number of relapses (flare-ups) and slow disability. Participants must have …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New lens design aims to halt worsening eyesight in children
Disease control ENROLLING_BY_INVITATIONThis study tests special 3D-designed defocus lenses to see if they can slow down myopia (nearsightedness) in children aged 6 to 14. The lenses are meant to control how the eye grows, reducing the need for stronger glasses over time. Researchers will track changes in vision and ey…
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Exercise as medicine: HIIT may slow glaucoma damage
Disease control OngoingThis study tests whether high-intensity interval training (HIIT) can improve eye health and slow disease progression in people with glaucoma. 168 adults aged 40-75 with open-angle glaucoma will be randomly assigned to either a supervised HIIT program or standard care with lifesty…
Phase: NA • Sponsor: Henner Hanssen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill could fight diabetic eye swelling
Disease control OngoingThis Phase 2 trial tests whether the oral drug tonabersat can reduce retinal swelling in people with diabetic macular edema who still have good vision. About 128 adults with type 1 or 2 diabetes will take either tonabersat or a placebo daily for several months. The main goal is t…
Phase: PHASE2 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study tests safer eye surgery for diabetics to protect vision
Disease control OngoingThis trial compares two surgical methods for diabetic patients with proliferative diabetic retinopathy who need vitrectomy. One method spares the central part of the retina (fovea), while the other removes the entire inner limiting membrane. The study will measure vision and eye …
Phase: NA • Sponsor: David Nashaat Shafik Fahmy • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Special lenses or eyedrops: which slows nearsightedness better in kids?
Disease control OngoingThis study tests whether special glasses called DIMS lenses can slow the worsening of nearsightedness (myopia) in children as well as low-dose atropine eyedrops do. About 242 children aged 6-12 with myopia will wear either DIMS lenses or regular glasses plus use atropine drops ni…
Phase: NA • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Own stem cells Gene-Hacked to fight rare hurler syndrome
Disease control OngoingThis study tests a one-time gene therapy for children with Hurler syndrome, a severe genetic disorder. Doctors take the child's own blood stem cells, add a working copy of the missing gene, and put them back. The goal is to help the body produce the enzyme it lacks, potentially s…
Phase: PHASE1, PHASE2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Dry eye drug combo safety trial pulled before it started
Disease control TerminatedThis study was designed to check the long-term safety of a new eye drop that combines two active ingredients (lifitegrast and perfluorohexyloctane) for people with dry eye disease. It was a follow-up for people who had already completed an earlier study. However, the trial was wi…
Phase: PHASE3 • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New glasses could slow kids' worsening eyesight
Disease control OngoingThis study tests whether special open-ring spectacle lenses can slow the progression of nearsightedness (myopia) in Chinese children aged 6 to 12. A total of 180 children will wear one of three lens designs for 12 months, with some continuing for another year. The goal is to see …
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could wet AMD patients get fewer eye shots? new study tests early treatment breaks
Disease control OngoingThis study compares two drugs, aflibercept and brolucizumab, for wet age-related macular degeneration (AMD). Instead of the usual three monthly loading doses, it tests starting with longer intervals between injections right away. The goal is to see if this approach works just as …
Phase: NA • Sponsor: Berner Augenklinik • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New glasses design may help stop Kids' eyesight from getting worse
Disease control OngoingThis study tests whether special glasses with a double helix lens design can slow the progression of myopia (nearsightedness) in children and adolescents aged 6 to 13. About 236 participants will wear either the new glasses or standard single-vision glasses for over 10 hours a da…
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug aims to stop NMOSD attacks in AQP4-positive patients
Disease control OngoingThis study tests an investigational drug called BAT4406F in 162 adults with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG). The drug is designed to reduce or prevent relapses by targeting certain immune cells. Participants receive either th…
Phase: PHASE2 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could peeling an extra layer during eye surgery prevent repeat detachment?
Disease control OngoingThis study compares two types of surgery for people with a detached retina. One group gets standard repair surgery, the other gets an extra step where a thin membrane is peeled away. Researchers want to see if this extra step lowers the chance of re-detachment and improves vision…
Phase: NA • Sponsor: Berner Augenklinik • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Double antibody attack: new hope for tough pancreatic cancer?
Disease control OngoingThis phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior trea…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Gene therapy trial aims to halt blindness in dry AMD
Disease control OngoingThis study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI eye check could save your sight: new trial tests smart screening for diabetes patients
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether using artificial intelligence (AI) to screen for diabetic eye disease during regular primary care visits helps more people get timely eye exams and follow-up care. About 1,700 adults with diabetes who haven't had an eye exam in the past year will take par…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
New app could spot eye disease from your couch
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a smartphone app called NEDS EyeCTester to see if it can help detect active eye disease early in people with conditions like optic nerve or macular disease. About 100 participants will use the app at home, and researchers will compare the results to standard…
Sponsor: Neuro-Eye Diagnostic Systems, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Brain scan breakthrough could save babies from rare disease
Diagnosis OngoingThis study looks at whether a special brain scan called diffusion tensor imaging (DTI) can help doctors find Krabbe disease in newborns and decide who needs urgent treatment. About 100 babies with a positive newborn screen or family history of Krabbe disease will be scanned and f…
Sponsor: University of Pittsburgh • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
New eye test could replace painful scrape for infection diagnosis
Diagnosis TerminatedThis study aimed to see if a soft membrane placed on the eye could diagnose microbial keratitis (a serious eye infection) better and more comfortably than the standard scrape test. Researchers planned to compare the two methods in adults with new corneal infections. However, the …
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Revolutionary eye camera could catch blindness early
Diagnosis OngoingThis study tests a new, ultra-high-resolution eye scanner that combines two imaging techniques to see the retina in 3D. Researchers will scan 10 healthy adults and 40 people with early or intermediate age-related macular degeneration (AMD). The goal is to improve early detection …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
AI eye exam could spot diabetes blindness before it starts
Diagnosis ENROLLING_BY_INVITATIONThis study is testing whether an artificial intelligence (AI) program can spot early signs of diabetic retinopathy—a condition that can lead to blindness—in people with prediabetes and diabetes. Researchers will take pictures of the retina and use the AI to analyze them. The goal…
Sponsor: University Hospital Tuebingen • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
Eye-Tracking tech could spot macular degeneration faster
Diagnosis OngoingThis study tests a device called AVIGA that tracks eye movements to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the device's results with standard eye exams to see if it can reliably spot disease activity. The goal is…
Sponsor: Tan Tock Seng Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Can Full-Body scans spot cancer early in High-Risk families?
Diagnosis OngoingThis study is testing whether whole body MRI scans can help find cancers early in children and adults with Li-Fraumeni syndrome, a genetic condition that greatly raises cancer risk. About 150 participants will receive annual whole body MRI scans for four years to see if they keep…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
AI eye exam could save premature Babies' sight
Diagnosis OngoingThis study tests an artificial intelligence system called i-ROP DL that analyzes images of the back of the eye. The goal is to see if it helps eye doctors more accurately diagnose retinopathy of prematurity (ROP), a condition that can cause blindness in premature infants. Researc…
Phase: NA • Sponsor: Siloam Vision • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New ultrasound technique could spot eye tumors without a biopsy
Diagnosis OngoingThis study tests a special ultrasound technique called Superb Microvascular Imaging (SMI) to see blood flow inside eye tumors. The goal is to help doctors tell benign from malignant tumors more accurately, especially when standard tests are unclear. Twenty-two adults with untreat…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
Cheap pill could save millions from blindness, major trial launches
Prevention OngoingThis study tests whether fenofibrate, a drug already used for high cholesterol, can prevent diabetic retinopathy from worsening in people with mild to moderate disease. About 560 adults with diabetes will take either fenofibrate or a placebo for up to 6 years. The goal is to see …
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Eye surgery trial to prevent blindness in stickler syndrome pulled before start
Prevention TerminatedThis study aimed to see if a surgical procedure called scleral buckling could prevent retinal detachment in people with Stickler syndrome, a genetic condition that raises the risk of vision loss. The plan was to treat one eye in patients aged 5 to 35 who had already lost vision i…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to protect young kenyan women from both HIV and partner violence
Prevention OngoingThis study tests a program called Tu'Washindi, designed by and for young women in Kenya. It combines support clubs and community sessions to help girls ages 15-24 reduce intimate partner violence and consistently use HIV prevention pills (PrEP). About 1,562 participants will be f…
Phase: NA • Sponsor: RTI International • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
Glasses that fight nearsightedness: a new hope for kids?
Prevention OngoingThis study tests whether special 'peripheral focus-out' glasses can prevent nearsightedness (myopia) in Chinese children aged 6 to 8. Over two years, 160 children will wear the glasses at least 8 hours a day. Researchers will measure changes in their vision to see if the glasses …
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Prevention
Last updated Jun 27, 2026 09:07 UTC
-
Dairy workers test special shoes to stop dangerous slips
Prevention OngoingThis study tests whether special slip-resistant shoes can help dairy workers avoid slipping on wet, slippery floors. About 22 full-time employees at a Danish dairy will wear different shoes and rate how slippery they feel each day. The goal is to find footwear that reduces fall r…
Phase: NA • Sponsor: Aalborg University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
New glasses aim to stop kids from becoming nearsighted
Prevention OngoingThis study tests whether special glasses can prevent nearsightedness (myopia) in children aged 6 to 9 who are not yet nearsighted but are at risk. About 388 children will wear the glasses for at least 8 hours a day for one year. Researchers will track how many children become nea…
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Prevention
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kids with rare liver disease: long-term drug study launched
Symptom relief OngoingThis study looks at the long-term safety and effectiveness of odevixibat in 70 people with Alagille syndrome, a rare genetic condition that affects the liver and other organs. The drug aims to reduce severe itching and improve bile flow. Participants who completed a prior 24-week…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
New eye drops aim to banish night glare after laser surgery
Symptom relief OngoingThis study tests whether phentolamine eye drops can improve vision in low light for people who had laser eye surgery and now see glare, halos, or starbursts at night. About 200 adults will use the drops or a placebo every evening for two weeks. The main goal is to see if more peo…
Phase: PHASE3 • Sponsor: Ocuphire Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New ICU checklist aims to make final moments more comfortable
Symptom relief OngoingThis study tests a structured team checklist called CMOT for when breathing support is removed from dying ICU patients. The goal is to reduce distress, which occurs in 30-59% of cases. Researchers will enroll 184 patients and ICU staff across four ICUs to see if the checklist is …
Phase: NA • Sponsor: Beth Israel Deaconess Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New eye drop aims to soothe dry eyes better than current option
Symptom relief OngoingThis study tests a new artificial tear called ABBV-444 against an existing brand, Refresh Optive, in 250 adults with dry eye disease. Participants use the assigned eye drops for 90 days. The goal is to see if the new formula improves eye comfort and surface health better than the…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Talking it out: therapy group aims to ease parents' stress in rare blindness condition
Symptom relief OngoingThis study tests whether group psychotherapy can help parents of children with Leber congenital amaurosis (LCA) feel better emotionally and handle stress. Forty parents will take part, with half joining therapy groups and the other half serving as a comparison. Researchers will m…
Phase: NA • Sponsor: Instituto de Genética Ocular • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Finger in mouth could cure dry eyes? small study tests odd technique
Symptom relief OngoingThis pilot study tests whether a specific hands-on technique inside the mouth can increase tear production in healthy adults aged 18-45. Thirty volunteers will have their tears measured before and after the procedure, with follow-up visits at 2 days and 1 week. The goal is to see…
Phase: NA • Sponsor: Edward Via Virginia College of Osteopathic Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Nerve-Zapping gadget could tame MS symptoms at home
Symptom relief OngoingThis study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New cataract lens aims to sharpen vision at Arm's length
Symptom relief ENROLLING_BY_INVITATIONThis study looks at how well a new type of lens, called Clareon TruPlus, helps people see clearly at intermediate distances (like a computer screen) after cataract surgery. About 50 adults with cataracts in both eyes will get this lens and be tested 12 weeks after surgery. The go…
Sponsor: Colvard Kandavel Eye Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Saffron study for dry eye pulled before it began
Symptom relief TerminatedThis study aimed to see if a saffron-based supplement called AffronEye® could improve dry eye symptoms in university staff and students. It planned to compare the supplement to a placebo over 84 days using eye tests and symptom questionnaires. However, the study was withdrawn bef…
Phase: NA • Sponsor: University of Alicante • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Sound-Guided gaze: new device aims to sharpen eye imaging for the visually impaired
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device that uses real-time sound feedback to help people with vision loss fix their gaze on a target. Participants hear sounds that guide their eyes back to center when they drift. The goal is to improve the quality of eye imaging by reducing blur from eye move…
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Could stem cell eye drops finally soothe stubborn dry eyes?
Symptom relief OngoingThis early-phase trial tests whether eye drops made from mesenchymal stem cells can safely relieve symptoms in 10 women aged 40-60 with dry eye disease that didn't improve with artificial tears. Participants use the drops twice daily for two weeks and are followed for three month…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Could a daily supplement soothe dry eyes?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether an oral supplement that targets gut bacteria can improve dry eye symptoms in adults with moderate evaporative dry eye disease. Over 8 weeks, 130 participants will take either the supplement or a placebo. The main goal is to see if symptoms, measured by a …
Phase: NA • Sponsor: Varol TUNALI • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New gel could make eye injections Pain-Free
Symptom relief ENROLLING_BY_INVITATIONThis study compares a new numbing gel (chloroprocaine HCl 3%) to standard eye drops plus a shot for pain relief during eye injections. About 236 adults with conditions like diabetic macular edema or age-related macular degeneration will take part. The goal is to see if the gel wo…
Phase: PHASE4 • Sponsor: Harrow Inc • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Spinal zaps and exercise may boost walking after injury
Symptom relief OngoingThis study tests whether combining motor skill training with a non-invasive spinal stimulation can improve walking, balance, and strength while reducing muscle spasticity in people with incomplete spinal cord injury. Twenty-eight participants will do a series of standing exercise…
Phase: NA • Sponsor: Shepherd Center, Atlanta GA • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Free glasses may help seniors bank from home
Symptom relief OngoingThis study gives free reading glasses and basic smartphone training to older adults in Bangladesh who receive government benefits. The goal is to see if better vision helps them use mobile banking more often and independently. About 571 people aged 48 to 70 with presbyopia (age-r…
Phase: NA • Sponsor: Queen's University, Belfast • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New eye gel could ease rosacea symptoms
Symptom relief ENROLLING_BY_INVITATIONThis Phase 2 trial tests a gel called lotilaner for people with moderate to severe ocular rosacea, a condition causing red, irritated eyes. About 155 adults will receive either the gel or a placebo to see if it is safe and helps symptoms. The study is currently enrolling by invit…
Phase: PHASE2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Diabetes cataract study pulled before starting
Symptom relief TerminatedThis study was designed to compare a tiny steroid insert (Dextenza) placed in the tear duct against standard steroid eye drops (prednisolone) after cataract surgery in people with diabetes. The goal was to see which better controls eye inflammation and swelling. However, the stud…
Phase: PHASE4 • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New laser surgery aims to sharpen vision for high astigmatism
Symptom relief OngoingThis study looks at how well SMILE PRO laser surgery corrects high astigmatism in people with nearsightedness. 113 patients aged 18 to 40 will have the procedure and be followed for a year to check vision sharpness, stability, and safety. The goal is to see if this advanced laser…
Phase: NA • Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Zap to see: electrical therapy for eye disease
Symptom relief OngoingThis study tests a treatment called transcorneal electrical stimulation to see if it can improve vision in people with retinitis pigmentosa, an eye disease that causes vision loss. Twenty-one adults with the condition received the therapy, and researchers measured changes in thei…
Phase: NA • Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug offered to cancer patients with severe wasting
Symptom relief NO_LONGER_AVAILABLEThis expanded access program gives seriously ill adults with advanced pancreatic cancer and cachexia (severe weight loss and muscle wasting) access to the experimental drug mifomelatide. Patients receive a daily injection for up to 13 weeks. The goal is to provide a potential tre…
Sponsor: Endevica Bio • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Can a common arthritis drug ease MPS pain? new trial seeks answers.
Symptom relief OngoingThis study tests whether adalimumab, a drug used for arthritis, can reduce pain and improve joint movement in people with MPS I, II, or VI. It includes children and adults aged 5 and older who have significant pain and limited joint motion. Participants receive either adalimumab …
Phase: PHASE1, PHASE2 • Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy may offer relief for chronic watery eyes
Symptom relief OngoingThis study compares using an anti-inflammatory eye drop (nepafenac) plus a lubricant versus a lubricant alone to treat watery eyes (epiphora) caused by narrowing of the tear duct opening. Researchers will measure changes in tear duct size and symptom severity in 68 Mexican adults…
Phase: PHASE4 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief ENROLLING_BY_INVITATIONThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Phase: NA • Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New laser aims to sharpen vision for the farsighted
Symptom relief OngoingThis study tests the safety and effectiveness of the TENEO 317 excimer laser used in LASIK surgery to treat farsightedness (hyperopia) with or without astigmatism. About 140 adults aged 22 and older will receive the laser treatment in one or both eyes and be followed for 12 month…
Phase: NA • Sponsor: Bausch & Lomb Incorporated • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Eye injection showdown: which drug restores vision better in diabetes patients?
Symptom relief ENROLLING_BY_INVITATIONThis study compares two common eye injection drugs, aflibercept and bevacizumab, in adults aged 30-60 with diabetic macular edema (fluid buildup in the retina causing vision loss). About 116 participants will receive monthly injections for two months. The goal is to see which dru…
Phase: NA • Sponsor: CMH Multan Institute of Medical Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Breast milk pacifier may soothe painful eye exams for preemies
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether giving premature babies a pacifier dipped in breast milk during eye exams for retinopathy of prematurity can reduce pain and improve comfort. About 56 infants born before 32 weeks will be randomly assigned to receive either standard care or the pacifier. …
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Light mask may soothe dry eyes in Graves' patients
Symptom relief ENROLLING_BY_INVITATIONThis study tests a low-level light therapy mask for dry eye disease in people with Graves' eye disease who haven't improved with standard treatments. Thirty adults will receive either the real light therapy or a sham device. The goal is to see if the treatment improves tear film …
Phase: NA • Sponsor: Grigore T. Popa University of Medicine and Pharmacy • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New drug aims to tame Sjögren's dryness and fatigue
Symptom relief OngoingThis study tests an experimental drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, an autoimmune disease causing dryness, fatigue, and pain. Participants receive either the drug or a placebo to see if it improves symptoms like dry eyes and mouth. T…
Phase: PHASE3 • Sponsor: Amgen • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
AI coach helps glaucoma patients ace tricky eye exam
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a computer-based AI tool can teach glaucoma patients how to take a visual field test more accurately. The test checks side vision, which is important for monitoring glaucoma. If the tool works, it could lead to more reliable results, fewer repeat visits, …
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Music before eye surgery may calm nerves, small study hints
Symptom relief OngoingThis study tests whether playing music through headphones for 15 minutes before cataract surgery can help reduce anxiety, pain, and improve satisfaction. Sixty adults having cataract surgery will either listen to music or wear headphones with no music. Researchers will measure st…
Phase: NA • Sponsor: Guangzhou First People's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Eye drops or full sleep? study tests best anesthesia for cataract surgery pain
Symptom relief OngoingThis study compares two ways to manage pain during cataract surgery: numbing eye drops (topical anesthesia) versus general anesthesia (being fully asleep). Researchers will follow 50 adults for up to six weeks after surgery, measuring pain, complications, and satisfaction. The go…
Phase: PHASE1, PHASE2 • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New study tests gentler tooth removal for faster implant healing
Symptom relief OngoingThis study compares two tools, piezotome and periotome, used for gentle tooth extraction before placing a dental implant right away in the front upper teeth. The goal is to see which tool better preserves bone and gum tissue, leading to improved healing and appearance. Thirty adu…
Phase: NA • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New eye surgery tech aims to prevent pressure spikes during cataract operations
Symptom relief OngoingThis study compares a new adaptive fluidics system to traditional methods during cataract surgery. The goal is to keep eye pressure stable and reduce risks. About 320 adults with lens diseases will take part. The new system adjusts fluid flow in real time to avoid sudden pressure…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New device aims to help NMOSD patients walk better
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device called MR-C-014 that uses sound to help people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. Thirty adults will use the device for 30 minutes, three times a week for 8 weeks. The main goals are to see if people find it acc…
Phase: NA • Sponsor: MedRhythms, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New hope for chronic hives? drug tested in small trial
Symptom relief TerminatedThis study tested whether ritlecitinib, a drug already approved for another condition, could safely reduce hives and itching in people with chronic spontaneous urticaria (CSU). The trial planned to enroll adults aged 18–65 who have had hives for over six weeks. Participants would…
Phase: PHASE2 • Sponsor: Ahuva D Cices • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New eye drop aims to zap dry eye discomfort in weeks
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether Acoltremon 0.003% eye drops can quickly relieve symptoms like burning, irritation, and blurriness in people with moderate-to-severe dry eye disease. Fifty adults will use the drops as directed and report their symptom changes over 28 days. The goal is to …
Sponsor: Colvard Kandavel Eye Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Fatigue study seeks to unravel mystery of exhaustion
Knowledge-focused OngoingThis study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …
Sponsor: National Center for Complementary and Integrative Health (NCCIH) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
AI eye scans aim to predict Sight-Threatening complication after retinal surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study investigates whether advanced eye imaging and artificial intelligence can predict proliferative vitreoretinopathy (PVR), a condition that can cause retinal detachment surgery to fail. Researchers will analyze scans from 100 patients with retinal detachment, some with P…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
NIH launches major study to unravel mysteries of rare genetic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to identify genetic, biochemical, and clinical factors linked to disease severity in people with Gaucher disease and other lysosomal storage disorders. Researchers will evaluate up to 1,000 participants, including patients, carriers, and healthy controls, to bette…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists track eye disease progression over five years
Knowledge-focused OngoingThis study follows 110 people who previously took part in the AREDS or AREDS2 trials to see how age-related macular degeneration (AMD) and cataracts change over time. Participants get a yearly eye exam, including vision tests and eye photos, and may give a blood sample. The goal …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Eye surgery silicone may change cornea cells, study finds
Knowledge-focused OngoingThis study looks at how silicone oil, used to repair detached retinas, affects the cells on the inner surface of the cornea. Researchers will measure cell density and shape changes in 40 patients at 1 and 3 months after surgery. They also want to see if any changes go away after …
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Real-World check: does aflibercept 8 mg hold up outside the lab?
Knowledge-focused OngoingThis observational study will follow 2,500 adults with vision loss from nAMD or DME who are already prescribed aflibercept 8 mg by their doctors. Researchers will collect data from routine visits over up to 24 months to see how vision changes. The goal is to understand how well t…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Withdrawn study sought better way to time eye injections
Knowledge-focused TerminatedThis study aimed to see if how well a person can fix their gaze relates to signs of active disease on eye scans in patients with age-related macular degeneration (ARMD) treated with antiVEGF injections. Researchers planned to follow patients for two years, measuring fixation qual…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists track Long-Term safety of experimental AMD therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The …
Sponsor: Perceive Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Eye disease progression under the microscope: 3-Year study launched
Knowledge-focused OngoingThis study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study checks if past drug still protects kidneys years later
Knowledge-focused TerminatedThis study looks at American Indians with type 2 diabetes who had early kidney disease and took a drug called losartan years ago. Researchers want to see if the benefits of that treatment still help protect their kidneys today. About 141 people who were in the earlier study or th…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate rare eye disease that blinds young boys
Knowledge-focused OngoingThis study looks at X-linked juvenile retinoschisis (XLRS), a rare inherited eye disease that causes vision loss in young males. Researchers will examine 351 participants, including affected males and female carriers, using eye exams, retinal photos, and genetic tests. The goal i…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks stargardt disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 80 people aged 8 to 50 with Stargardt disease, a genetic eye condition that causes vision loss. Researchers will monitor how the disease changes over time using eye imaging. The goal is to better understand the disease and prepare for future clinical trials.
Sponsor: AAVantgarde Bio Srl • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Stem cell eye therapy: 5-Year safety watch begins
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows people who received a stem cell treatment for macular degeneration to see if any late side effects appear more than 5 years later. Participants fill out a yearly questionnaire about eye problems, infections, immune disorders, cancer, or other health changes. Th…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Eye drop study reveals hidden changes in eye bacteria
Knowledge-focused OngoingThis study looks at how a common glaucoma eye drop (latanoprost with preservatives) changes the natural bacteria living on the eye's surface. Researchers will compare the eye bacteria of 45 newly diagnosed glaucoma patients before and after at least 6 months of treatment. The goa…
Sponsor: University of Ioannina • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Eye strain test may forecast glaucoma course
Knowledge-focused OngoingThis study looks at whether images of the optic nerve head taken at two different eye pressures can predict how glaucoma will change over time. Researchers will compare these strain measurements to actual vision loss in 130 glaucoma patients. The goal is to develop a new biomarke…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Ground-Level vision test could help retinitis pigmentosa patients walk better
Knowledge-focused TerminatedThis study was designed to see if a new method of measuring the visual field—by projecting vision zones on the ground—helps people with retinitis pigmentosa understand their remaining sight and improve their walking rehabilitation. The trial was withdrawn before enrolling any par…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive Real-World study tracks roche eye drugs in 6,000 patients
Knowledge-focused OngoingThis study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New registry tracks vision loss in rare eye diseases
Knowledge-focused OngoingThis study collects information from about 889 people with inherited retinal diseases (IRDs) to understand how vision changes over time. Participants have their eyesight and visual field tested regularly. The goal is to learn more about the natural course of these rare eye condit…
Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Major study on rare childhood liver diseases halted
Knowledge-focused TerminatedThis study followed children and young adults with genetic liver diseases that cause bile buildup. The goal was to track how these diseases progress over time, including the need for liver transplants or other complications. No treatments were tested; the aim was simply to learn …
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Which reading glasses give the best view? new study puts three lens designs to the test
Knowledge-focused OngoingThis study compares three types of progressive lenses to see which provides the widest clear vision at distances from 4 meters down to 25 centimeters. About 26 presbyopic participants will test each lens in a random, double-blind order. The goal is to help eye doctors choose the …
Phase: NA • Sponsor: University of Seville • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to tackle vision problems in upper manhattan
Knowledge-focused TerminatedThis study aims to help adults aged 40 and older in Upper Manhattan get better eye care. It will offer free eye screenings at local health centers and senior centers, and provide support like scheduling appointments and transportation. The goal is to see if this extra help leads …
Phase: NA • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive genetic study aims to unlock secrets of rare metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Eggs on the menu: could a daily dozen slow vision loss?
Knowledge-focused OngoingThis pilot study tests whether older adults with intermediate age-related macular degeneration (AMD) can eat 2 or 4 whole eggs daily for 5 months. The main goal is to see if people can stick with the diet, not to prove eggs improve vision. Researchers will also measure changes in…
Phase: EARLY_PHASE1 • Sponsor: Kathryn Starr • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Researchers track Long-Term safety of experimental eye cancer drug
Knowledge-focused OngoingThis registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving ne…
Sponsor: Aura Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Diabetes drug eye risk under microscope
Knowledge-focused OngoingThis study looks at how newer diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) affect the eyes of people with type 2 diabetes. Researchers will monitor 40 adults who take metformin and are starting these newer drugs. The goal is to see if these drugs cause any …
Sponsor: University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Smart home tech could spot early dementia signs
Knowledge-focused OngoingThis Stanford study is testing whether non-intrusive sensors placed in the home can automatically track neuropsychiatric symptoms like mood changes and agitation in older adults. Researchers will enroll 25 participants with or at risk of mild cognitive impairment or dementia, alo…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Rural clinics get help to catch diabetic eye disease early
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether a program called I-SITE can help rural health clinics use teleophthalmology (remote eye exams) to screen more diabetic patients for eye problems. Up to 10 health systems and 10,000 patients will take part. The goal is to see if screening rates improve …
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New study tracks Faricimab's Real-World impact on major eye diseases
Knowledge-focused OngoingThis study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and ho…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Japanese database study tracks Real-World use of eye injection aflibercept 8 mg
Knowledge-focused OngoingThis observational study examines how aflibercept 8 mg, an injection into the eye, is used in routine care for patients in Japan with age-related macular degeneration or diabetic macular edema. Researchers will analyze claims data from about 3000 patients to understand patient ch…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Special lens may slow nearsightedness – tiny study looks at how
Knowledge-focused OngoingThis study looks at how a new type of eyeglass lens affects the back layer of the eye (the choroid) in children with worsening nearsightedness. Ten children already in a larger study will have their eye thickness measured with a special camera. The goal is to understand if the le…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Sjögren's study dives deep into immune clues in spit and blood
Knowledge-focused OngoingThis study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New glasses for nearsighted kids put to the test
Knowledge-focused OngoingThis study looks at how well children with nearsightedness (myopia) see when wearing special glasses. The 51 participants are already part of a larger study on myopia progression. Researchers will measure reading speed and vision in different lighting to see how the lenses perfor…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Dry eye study seeks better ways to measure disease
Knowledge-focused OngoingThis study tracks 378 people with moderate to severe dry eye disease and healthy volunteers to see how signs, symptoms, and biomarkers change after treatment with either Vevye or Xiidra eye drops. The goal is to find better ways to measure the disease and its response to therapy.…
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
10,000 people to have eye and skin pigments measured in nutrition study
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand how diet affects the eyes and skin by measuring natural pigments called carotenoids. Researchers will use non-invasive methods to check levels in the eye and skin, and also test blood in some participants. Anyone age 7 or older having a routine eye e…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Do special glasses keep working after kids stop wearing them?
Knowledge-focused OngoingThis study follows 90 children who previously wore special spectacle lenses to slow nearsightedness (myopia). After stopping the lenses, researchers measure how much their vision changes over 12 months. The goal is to see if the benefits of the lenses last after use ends.
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New eye tests could speed up retinitis pigmentosa treatment trials
Knowledge-focused OngoingThis study aims to find better ways to measure how retinitis pigmentosa (a genetic eye disease that causes vision loss) progresses over time. Researchers will use advanced imaging and vision tests in 40 people with specific genetic forms of the disease. The goal is to identify re…
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New glasses tested to see how Kids' eyes focus
Knowledge-focused OngoingThis study looks at how the eye focuses (lag of accommodation) when children with nearsightedness wear special DOT pattern spectacle lenses compared to regular glasses. About 30 kids aged 6 to 18 will have their vision measured at distance and close-up with each lens type. The go…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New lenses may reveal how to slow nearsightedness in kids
Knowledge-focused OngoingThis study tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can change the thickness of the choroid, a layer of blood vessels in the eye. Researchers will measure these changes in 30 children aged 8-14 with normal vision after wearing the len…
Phase: NA • Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New hope for diabetic eye disease? Real-World study tests steroid implant
Knowledge-focused OngoingThis observational study follows about 236 adults with diabetic macular edema (DME) who did not respond well to anti-VEGF injections and are now starting treatment with a dexamethasone implant (DEX-I). The implant slowly releases steroid medication into the eye. Researchers will …
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Why do some blind people see things that Aren't there? new study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how common Charles Bonnet Syndrome (CBS) is in people with vision loss from conditions like macular degeneration or glaucoma. CBS causes complex visual hallucinations without mental illness. Researchers will survey 640 participants to measure how often it happ…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Eye fluid test could spot dry AMD changes early
Knowledge-focused OngoingThis study is testing whether taking a tiny sample of fluid from the front of the eye is safe for people with dry age-related macular degeneration (AMD). Researchers will analyze proteins in the fluid to see if they change over time. The study includes 50 adults aged 50 to 89, so…
Phase: NA • Sponsor: ClinOmicsAI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists hunt for clues to ichthyosis in skin and blood
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at skin and blood samples from 200 people with ichthyosis (a genetic condition causing dry, scaly skin) and healthy volunteers. Researchers want to find specific markers that could help them understand the disease better and develop new treatments. No treatment i…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Which training method produces better eye surgeons?
Knowledge-focused OngoingThis study compares two methods for teaching cataract surgery to ophthalmology residents. One group learns steps in the usual order, while the other learns easier steps first. Researchers will measure how well residents perform surgery and how often complications occur. The goal …
Phase: NA • Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
AI predicts hidden glaucoma risk after LASIK in 10,000-Patient study
Knowledge-focused OngoingThis study uses artificial intelligence to predict true eye pressure after corneal refractive surgery like LASIK or SMILE. Standard eye pressure measurements can be falsely low after these surgeries, masking glaucoma risk. Researchers will analyze data from over 10,000 participan…
Sponsor: Tianjin Eye Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks rare disease MLIV to map its natural course
Knowledge-focused OngoingThis study looks back at medical records of 50 people with Mucolipidosis Type IV (MLIV) to learn how the disease typically progresses. Researchers want to know when children reach or lose developmental milestones, how their movement and vision change, and what lab results look li…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
500 eye melanoma patients share their quality of life journey
Knowledge-focused OngoingThis study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists track vision loss in rare genetic eye disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 50 people with a rare inherited eye condition called PRPF31-related retinal dystrophy (RP11) to see how their vision changes over time. Researchers will measure things like visual acuity, retinal thickness, and quality of life using eye exams and questionnaires…
Sponsor: PYC Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Eye disease study lays groundwork for gene therapy breakthrough
Knowledge-focused TerminatedThis study looks at a rare, inherited eye disease called CNGB1 retinitis pigmentosa that causes gradual vision loss and blindness. Researchers want to learn how the disease progresses by using eye exams and imaging tests over three years. The goal is to find the best ways to meas…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
5-Minute MRI could spot brain changes in rare disorder
Knowledge-focused OngoingThis study tests a new, fast MRI method that takes about 5 minutes, uses no contrast dye, and often no sedation, even in children. Researchers will scan 80 people with Sturge-Weber syndrome (ages 3 months to 30 years) to see if this quick MRI can accurately detect brain abnormali…
Phase: NA • Sponsor: Wayne State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Robot eye scanner study pulled before it started
Knowledge-focused TerminatedThis study planned to test a new robotic system that helps take detailed 3D images of the far edges of the retina, an area that is hard to see with standard eye scanners. The goal was to see if the robot could make imaging easier and more comfortable for healthy adults. However, …
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Can we predict heart disease in kids? new study seeks answers
Knowledge-focused OngoingThis study looks at over 1,000 South African children ages 5 to 9 to understand why some develop early signs of high blood pressure and heart problems. Researchers will measure blood pressure, body fat, and fitness, and test blood for early warning markers. The goal is to find wa…
Sponsor: North-West University, South Africa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Could your phone replace a Post-Surgery eye check?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a smartphone app (WHOeyes) plus a symptom questionnaire can safely replace the standard in-clinic checkup one week after cataract surgery. About 334 people aged 50–80 with uncomplicated cataracts will either use the app at home or come to the clinic. The …
Phase: NA • Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Eye fluid analysis may unlock secrets of rare eye condition
Knowledge-focused OngoingThis pilot study examines proteins in the vitreous (the gel-like fluid inside the eye) of patients with pseudoexfoliation syndrome (PEX), a condition that can lead to glaucoma. Researchers will compare protein levels between eyes with and without PEX in 24 adults undergoing eye s…
Phase: NA • Sponsor: Prim. Prof. Dr. Oliver Findl, MBA • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Glaucoma surgery checked 5 years later: does it hold up?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 250 people with open-angle glaucoma who had a new type of surgery called CycloPen, which aims to improve fluid drainage from the eye. Researchers will measure eye pressure at 3, 4, and 5 years after surgery to see if the benefits last. The goal is to understand…
Sponsor: Iantrek, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Premature Babies' vision tracked years after ROP treatment
Knowledge-focused OngoingThis study follows about 100 premature babies who were treated for retinopathy of prematurity (ROP) in an earlier study. Researchers will check their eyesight and overall development over time to see how they are doing. No new treatment is given in this study.
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused TerminatedThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Home infusions may help patients stick to treatment
Knowledge-focused OngoingThis study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to continue their IV treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico. No new treatments are given; the goal is to un…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Cataract surgery tech showdown: laser vs standard handpieces
Knowledge-focused TerminatedThis study was designed to compare two newer technologies for cataract surgery: a femtosecond laser and a special handpiece that monitors eye pressure. The goal was to see if these tools cause less damage to the cornea and use less energy than standard methods. However, the study…
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Video program aims to ease mental toll of rare eye cancer
Knowledge-focused OngoingThis study tests whether a video-based educational program can help people who have had uveal melanoma (a rare eye cancer) better understand their disease and feel more in control. About 108 adults who completed treatment are randomly assigned to watch the video or receive usual …
Phase: NA • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Eye pressure clue could sharpen vision after retinal surgery
Knowledge-focused OngoingThis study looks at whether having low eye pressure before surgery changes how well doctors can predict your final glasses prescription after a combined cataract and retinal detachment repair. Researchers will compare two groups of people: those with low eye pressure and those wi…
Phase: NA • Sponsor: Kazakh Eye Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Massive diabetes biobank aims to predict kidney and heart risks
Knowledge-focused OngoingThis study is building a large biobank of health information and blood samples from 48,000 people with diabetes in Hong Kong. Researchers will analyze genetic and other markers to find better ways to predict serious complications like kidney failure, heart disease, and stroke. Th…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Eye tests may predict vision after corneal transplant
Knowledge-focused OngoingThis study looks at how keratoconus, a disease that thins and bulges the cornea, affects electrical signals in the eye and brain. Researchers will measure these signals in 50 adults with different stages of keratoconus using standard eye tests. The goal is to see if these measure…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New national registry aims to improve care for rare genetic polyposis syndromes
Knowledge-focused OngoingThis study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Eye rosacea study seeks safer antibiotic use
Knowledge-focused OngoingThis study looks at how different doses of the antibiotic doxycycline affect antibiotic resistance in people with ocular rosacea, an inflammatory eye condition. Researchers will compare a low anti-inflammatory dose (40 mg daily) with a standard antibiotic dose (200 mg daily) and …
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Eye-Opening study: why do some Kids' contact lenses work better for nearsightedness?
Knowledge-focused OngoingThis study examines protein differences in the tears of nearsighted children who use special overnight contact lenses (orthokeratology) to slow down worsening vision. Researchers want to understand why some children get better control of their myopia than others. The study involv…
Sponsor: Vejle Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Eye disease study aims to speed up future treatments
Knowledge-focused OngoingThis study follows 103 adults with a genetic eye condition called retinitis pigmentosa caused by EYS mutations. Researchers will track changes in vision and eye structure over 4 years. The goal is to better understand how the disease progresses so that future clinical trials can …
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New eye software could sharpen inflammation detection
Knowledge-focused OngoingThis study is testing a new software that measures eye inflammation from standard images taken during routine care. Researchers will enroll 50 people with uveitis, an inflammatory eye disease, to see if the software can detect meaningful changes in inflammation. The goal is to he…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study seeks clues to rare brain disorder
Knowledge-focused OngoingThis study looks at 600 people with Sturge-Weber syndrome, a rare condition that affects the brain and skin. Researchers want to find out what causes the disease to get worse over time. They will study genes, blood vessel changes, and substances in urine to better predict and man…
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Contact lens stress test for fuchs dystrophy eyes
Knowledge-focused TerminatedThis study aimed to compare how corneas with Fuchs endothelial corneal dystrophy (FECD) and healthy corneas swell and recover after wearing a contact lens for three hours. Researchers planned to measure corneal thickness before and after the lens was removed, tracking swelling an…
Phase: PHASE1, PHASE2 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Eye scans reveal how well glaucoma stents are placed
Knowledge-focused OngoingThis study looks at 116 adults who had glaucoma stent surgery up to 2 years ago. Researchers use a special eye scan (OCT) to check if the tiny stents are in the right position and how that affects eye pressure. The goal is to learn how often stents are misplaced and whether prope…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Eye disease study seeks better ways to measure sight loss
Knowledge-focused OngoingThis study follows 12 adults with severe retinitis pigmentosa, a genetic eye disease that causes vision loss. Researchers want to find out which vision tests people with very low sight can reliably perform and how their vision changes over one year. The goal is to improve future …
Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Does donor diabetes impact corneal transplant outcomes?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether corneas from donors with diabetes work as well as those from donors without diabetes after a specific type of corneal transplant called DMEK. Researchers will track 570 participants for 5 years to measure cell loss and overall transplant success. The g…
Phase: NA • Sponsor: Case Western Reserve University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New scanner could help surgeons predict cataract hardness
Knowledge-focused OngoingThis study tests a special scanning device that measures how stiff the eye's lens is in people with cataracts. Researchers want to see if this stiffness measurement matches standard cataract grading and surgery energy needed. 50 adults with cataracts will be scanned before surger…
Sponsor: Prim. Prof. Dr. Oliver Findl, MBA • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Healthy Kids' eye data may help spot diabetes damage early
Knowledge-focused OngoingThis study aims to build a database of normal eye measurements from healthy children aged 6-15. Researchers will then compare these measurements with those from children who have type 1 diabetes. The goal is to better understand early signs of diabetic retinopathy, a condition th…
Phase: NA • Sponsor: University Hospital Ostrava • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New Light-Based technique reveals corneal strength in real time
Knowledge-focused ENROLLING_BY_INVITATIONThis study uses a special light-based technique called Brillouin microscopy to measure the stiffness of the cornea in people with keratoconus, a condition where the cornea thins and bulges. Researchers will compare measurements before and after treatments like corneal cross-linki…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Russian NMOSD patients under the microscope: no new drug, just Real-World data
Knowledge-focused TerminatedThis study is not testing a new treatment. Instead, it observes how 100 adults with a rare autoimmune disease called NMOSD are managed in everyday Russian clinics. Researchers will collect medical records and follow patients over time to understand their symptoms, treatments, and…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Can telemedicine help prevent blindness in diabetes patients?
Knowledge-focused OngoingThis study tests a program called I-SITE that helps clinics use teleophthalmology—taking eye photos during regular doctor visits—to increase screening for diabetic retinopathy. Over 12,000 patients with diabetes from urban health systems are included. The goal is to see if this a…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Healthy volunteers help unlock secrets of vision recovery
Knowledge-focused OngoingThis study looks at how the brain changes and adapts after losing central vision, which happens in conditions like macular degeneration. Researchers are testing different training tasks in 120 healthy adults aged 18-30 to measure improvements in eye movements and focus. The goal …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
800 NMOSD patients join landmark registry to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow about 800 adults with neuromyelitis optica spectrum disorder (NMOSD) across North America. Researchers will collect data on how the disease presents, progresses, and is managed in real-world settings. No experimental treatments are given; the …
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can less radiation treat eye cancer just as well?
Knowledge-focused OngoingThis study tracks 42 people with ocular melanoma who received radiation therapy via eye plaque brachytherapy. Researchers want to see if using lower radiation doses can still keep the cancer from coming back while reducing harmful side effects. The goal is to find the safest effe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Eye disease study aims to pave way for future treatments
Knowledge-focused OngoingThis study follows 127 people with a genetic eye condition called USH2A-related retinal degeneration, which can cause vision loss and hearing problems. Researchers measure changes in vision, retinal sensitivity, and mobility over several years. The goal is to understand how the d…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Tear and blood molecules may unlock secrets of eye allergies
Knowledge-focused OngoingThis study compares small molecules called microRNAs in the tears and blood of 40 people with allergic conjunctivitis versus healthy individuals. The goal is to find patterns that could help diagnose the condition and reveal new targets for treatment. Participants are aged 5 to 3…
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists map rare blindness to speed future cures
Knowledge-focused OngoingThis study follows 44 people with a rare genetic form of Usher syndrome caused by PCDH15 mutations. Over 48 months, researchers measure how their vision changes using eye exams and imaging. The goal is to identify the best ways to track disease progression, which will help design…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Childhood eye cancer survivors share life lessons in landmark study
Knowledge-focused OngoingThis study looks at the long-term health and quality of life of adults who had retinoblastoma, a rare eye cancer, as children. Researchers want to understand how survivors are doing physically and emotionally, and what challenges they face. The goal is to improve care and follow-…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Eye pain mystery: scientists probe nerve link in dry eye sufferers
Knowledge-focused TerminatedThis study looks at how common nerve problems are in people who feel eye discomfort. Researchers will test 1,000 participants to see if their pain is linked to nerve damage rather than just dry eye. The goal is to better understand these conditions and improve diagnosis.
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Scientists track rare eye disease to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Which reversal drug causes fewer bathroom problems after surgery?
Knowledge-focused OngoingThis study reviewed records of 70,000 adults who had non-urinary surgery under general anesthesia. It compared two drugs used to reverse muscle relaxants: sugammadex and neostigmine (given with atropine or glycopyrrolate). The goal was to see which drug is linked to fewer cases o…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
500 patients to help improve cataract lens implants
Knowledge-focused ENROLLING_BY_INVITATIONThis study is observing 500 people having cataract surgery to see how well different types of artificial lens implants (monofocal, multifocal, and toric) perform. Researchers will measure vision and patient satisfaction 3-6 months after surgery. The goal is to understand what mak…
Phase: NA • Sponsor: Aston University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Missing fine hairs around eye may signal skin cancer
Knowledge-focused TerminatedThis study aimed to see if losing tiny, fine hairs (vellus hairs) on the eyelid could be a sign of skin cancer. Researchers planned to check patients before a biopsy and compare hair loss with the biopsy result. The study was withdrawn before it started, so no data was collected.
Sponsor: NHS Lothian • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
600 Kids' eye surgeries tracked for a decade: what happens next?
Knowledge-focused OngoingThis study follows 600 children aged 0-16 who had cataract surgery after an eye injury. Researchers will check vision, eye growth, and complications over 5-10 years to understand long-term healing and guide better care. No new treatment is tested—just careful observation of past …
Sponsor: Jin Yang • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New eye test could unlock secrets of ocular pain
Knowledge-focused TerminatedThis study looks at how well a new test called quantitative sensory testing (QST) can measure nerve function in the eye. Researchers will use heat, cold, and vibration to see how people with dry eye disease or corneal nerve damage respond. The goal is to better understand eye pai…
Phase: NA • Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Massive gene hunt launched for mysterious mitochondrial diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to discover new genetic mutations that cause mitochondrial disorders by analyzing tissue samples from up to 6,900 participants. It includes people with suspected or known mitochondrial diseases, such as MELAS or Leigh's Disease, who lack a genetic diagnosis. The r…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Eye scan could spot hidden nerve pain in dry eye sufferers
Knowledge-focused TerminatedThis study is testing whether a special microscope (in vivo confocal microscopy) can reliably detect tiny nerve growths called microneuromas in the cornea, which may be a sign of neuropathic corneal pain. Researchers will scan the eyes of 438 adults with dry eye or ocular pain to…
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
AI tutor for eye surgery: stanford tests ChatGPT to clear up lens confusion
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a custom AI chatbot can help cataract patients better understand their artificial lens choices before meeting their surgeon. About 70 adults will either get standard counseling or standard counseling plus an AI explanation. The goal is to see if the AI to…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists launch major effort to unravel mysteries of rare brain and spinal cord diseases
Knowledge-focused OngoingThis study follows 150 people with rare neuroimmunologic disorders like neuromyelitis optica and transverse myelitis. Researchers collect medical data and blood samples over time to learn what causes inflammation and why some patients respond to treatments while others do not. Th…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Massive brain chart project aims to spot Alzheimer's and MS earlier
Knowledge-focused ENROLLING_BY_INVITATIONThis study will collect brain scans from over 10,000 healthy people in China to create standard brain charts. These charts will show what a normal brain looks like at different ages. Doctors can then compare a patient's brain scan to these charts to help diagnose diseases like mu…
Sponsor: Beijing Tiantan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can a glass of water or a change in posture spike your eye pressure?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how changing your body position or drinking water can cause temporary spikes in eye pressure. Researchers will measure these changes in healthy volunteers and in people with glaucoma or autonomic dysfunction. The goal is to better understand what challenges th…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can blood stem cells predict diabetic eye disease?
Knowledge-focused OngoingThis study looks at blood stem cells (called EPCs) in people with and without diabetes to see if they work differently. Researchers want to know if these cells can predict diabetic retinopathy, an eye disease that can cause vision loss. The study involves 78 adults, including 39 …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Hidden blood vessels may shield eyes from blindness, new study suggests
Knowledge-focused OngoingThis study looks at a specific type of blood vessel growth under the retina, called non-exudative type 1 macular neovascularization (MNV), in people with age-related macular degeneration (AMD). Researchers want to see if these vessels actually help preserve vision rather than har…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Cataract surgery device showdown canceled before it began
Knowledge-focused TerminatedThis study aimed to compare two different surgical systems for cataract removal in adults with moderate to severe cataracts. The goal was to see which system was safer and more efficient. However, the study was withdrawn before any participants were enrolled, so no results are av…
Phase: NA • Sponsor: Alcon Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Eye surgery showdown: UNITY VCS vs CONSTELLATION trial pulled
Knowledge-focused TerminatedThis study aimed to compare two surgical systems, UNITY VCS and CONSTELLATION, for treating various eye conditions like macular holes and retinal detachment. It was designed for adults needing vitreoretinal surgery. However, the trial was withdrawn before enrolling any participan…
Phase: NA • Sponsor: Alcon Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Could a workout save your sight? new study investigates
Knowledge-focused OngoingThis study aims to find out if changes in blood markers can predict whether exercise helps improve vision. Researchers will compare aerobic exercise to balance training in 14 sedentary adults aged 18 to 89 with vision disorders. The goal is to understand how exercise might protec…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New 3D-CT model could help doctors safely manage airways in infants with rare facial condition
Knowledge-focused OngoingThis study is developing a prediction tool using 3D-CT scans to identify which infants with Pierre Robin sequence (a condition with a small jaw and tongue that can block the airway) are likely to have a difficult time during breathing tube placement for surgery. Researchers will …
Sponsor: Nanjing Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye fluid test may personalize uveitis treatment
Knowledge-focused OngoingThis study tests whether analyzing fluid from the eye can predict which immunosuppressive drug will work best for people with non-infectious uveitis, an eye inflammation condition. About 220 participants who haven't responded well to steroids will provide eye fluid and blood samp…
Phase: NA • Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye cancer survivors: does anesthesia affect the brain?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how cancer treatment and multiple rounds of anesthesia affect thinking skills, emotions, and quality of life in people who survived retinoblastoma (a rare eye cancer) or were at risk for it. Researchers will test memory, attention, and other brain functions in…
Sponsor: Amsterdam University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye scanner software update put to the test
Knowledge-focused OngoingThis study compares a new software version (1.5) of the ANTERION eye imaging device against the older cleared version (1.2.4). Researchers will check if the new software gives consistent and accurate measurements of eye structures like cornea thickness and lens thickness. The stu…
Sponsor: Heidelberg Engineering GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC